Chemioterapia nowotworów (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Chemioterapia nowotworów" in Polish language version.

refsWebsite

Global rank Polish rank

249nih.gov

4^th place

7^th place

232doi.org

2^nd place

6^th place

12web.archive.org

1^st place

10books.google.com

3^rd place

27^th place

4mp.pl

8,738^th place

165^th place

3cancer.gov

1,684^th place

2,913^th place

2czytelniamedyczna.pl

low place

1,047^th place

2cancernetwork.com

low place

2aacrjournals.org

8,869^th place

9,541^st place

2nowotwory.edu.pl

low place

2termedia.pl

low place

624^th place

2cancer.org

3,680^th place

6,345^th place

2viamedica.pl

low place

585^th place

1cancerresearchuk.org

8,489^th place

low place

1cmkp.edu.pl

low place

770^th place

1wiley.com

222^nd place

228^th place

1wikidata.org

43^rd place

484^th place

1zalecenia.med.pl

low place

1iiarjournals.org

low place

1pthit.pl

low place

1sagepub.com

731^st place

848^th place

1akademiamedycyny.pl

low place

4,031^st place

1njmonline.nl

low place

1kup.at

low place

1cancer.ca

low place

1cdc.gov

218^th place

561^st place

aacrjournals.org

D.D. Pinkel D.D., The use of body surface area as a criterion of drug dosage in cancer chemotherapy, „Cancer Research”, 18 (7), 1958, s. 853–856, PMID: 13573353 [dostęp 2024-04-22] (ang.).
M.M.M.M. Keane M.M.M.M. i inni, Chemotherapy augments TRAIL-induced apoptosis in breast cell lines, „Cancer Research”, 59 (3), 1999, s. 734–741, PMID: 9973225 [dostęp 2024-04-30] (ang.).

akademiamedycyny.pl

AgnieszkaA. Skotnicka AgnieszkaA., EdmundE. Grześkowiak EdmundE., Substancje neuroprotekcyjne o potencjalnym zastosowaniu w neuropatii obwodowej indukowanej chemioterapią, „Farmacja Współczesna”, 2, 2009, s. 86–90 [dostęp 2024-05-05] .

books.google.com

JanosJ. Fischer JanosJ., C. RobinC.R. Ganellin C. RobinC.R., Analogue-based Drug Discovery II, ISBN 978-3527325498 .
James S.J.S. Olson James S.J.S., Making Cancer History: Disease and Discovery at the University of Texas M. D. Anderson Cancer Center, s. 104, ISBN 978-0801890567 .
FrancoF. Cavalli FrancoF. i inni, Textbook of Medical Oncology, wyd. 2, CRC Press, 2000, s. 73–74, ISBN 978-0-415-47748-2 [dostęp 2024-04-19] .
EdwardE. Chu EdwardE., Vincent T.V.T. DeVita Vincent T.V.T., jr., Physicians’ Cancer Chemotherapy Drug Manual, wyd. 14, Jones & Bartlett Learning, 2014, s. 7–8, ISBN 978-1284026856 [dostęp 2024-04-19] .
LisaL. Dougherty LisaL., JulieJ. Lamb JulieJ. (red.), Intravenous Therapy in Nursing Practice, John Wiley & Sons, 2009, s. 471, ISBN 978-1-4051-4647-0 .
Connie HenkeC.H. Yarbro Connie HenkeC.H., MichelleM. Goodman MichelleM., Margaret HansenM.H. Frogge Margaret HansenM.H., Cancer Nursing: Principles And Practice, Jones & Bartlett Learning, 2005, s. 369, ISBN 978-0763747206 .
Keith MK.M. Bellizzi Keith MK.M., MargotM. Gosney MargotM., Cancer and Aging Handbook: Research and Practice, Hoboken: John Wiley & Son Inc., 2012, s. 410, ISBN 978-0-470-87442-4 .
Hyman J.H.J. Zimmerman Hyman J.H.J., Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver, Philadelphia: Lippincott Williams & Wilkins, 1999, s. 673, ISBN 0-7817-1952-6 .
Sai-Ching JimS.Ch.J. Yeung Sai-Ching JimS.Ch.J., Carmen P.C.P. Escalante Carmen P.C.P., Robert F.R.F. Gagel Robert F.R.F., Medical Care of the Cancer Patient, wyd. 1, s. 22, ISBN 978-1607950080 .
UrsulaU. Rüther UrsulaU., ChristaCh. Nunnensiek ChristaCh., Hans-JoachimH.J. Schmoll Hans-JoachimH.J., Secondary Neoplasias Following Chemotherapy, Radiotherapy and Immunosuppression, Karger, 2000, s. 202–224, ISBN 978-3-8055-7116-6 .

cancer.ca

Canadian CancerC.C. Society Canadian CancerC.C., Lung damage and chemotherapy [dostęp 2014-11-01] [zarchiwizowane z adresu 2014-11-01] .

cancer.gov

National CancerN.C. Institute National CancerN.C., Chemotherapy-Induced Peripheral Neuropathy, 2010-02-23 [dostęp 2014-10-24] [zarchiwizowane z adresu 2014-10-24] .
v, Fatigue [dostęp 2014-11-06] .
v, Hair Loss (Alopecia) [dostęp 2014-11-04] .

cancer.org

American CancerA.C. Society American CancerA.C., Feeling Tired vs. Cancer-Related Fatigue [dostęp 2014-11-06] .
g, Second Cancers Caused by Cancer Treatment [dostęp 2014-11-10] .

cancernetwork.com

RamyaR. Thota RamyaR., James M.J.M. Pauff James M.J.M., Jordan D.J.D. Berlin Jordan D.J.D., Treatment of metastatic pancreatic adenocarcinoma: a review, „Oncology”, 28 (1), 2014, s. 70–74, PMID: 24683721 [dostęp 2024-04-22] (ang.).
David H.D.H. Henry David H.D.H., The role of intravenous iron in cancer-related anemia, „Oncology”, 20 (8 Suppl 6), 2006, s. 21–24, PMID: 16925107 [dostęp 2024-04-30] (ang.).

cancerresearchuk.org

The history of chemotherapy, Cancer Research UK [dostęp 2015-02-10] [zarchiwizowane z adresu 2014-11-10] .

cdc.gov

CDC.gov, Occupational exposure to antineoplastic agents [dostęp 2014-12-23] .

cmkp.edu.pl

eu.cmkp.edu.pl

JoannaJ. Didkowska JoannaJ. i inni, Podstawy onkologii klinicznej, JanuszJ. Meder (red.), Warszawa: Centrum Medyczne Kształcenia Podyplomowego, 2011, ISBN 978-83-62110-24-7 .

czytelniamedyczna.pl

KrzysztofK. Warzocha KrzysztofK., EwaE. Lech-Marańda EwaE., Diagnostyka i leczenie chłoniaków nieziarniczych, „Postępy Nauk Medycznych”, 2011 .
GrzegorzG. Nawrocki GrzegorzG., Marek P.M.P. Nowacki Marek P.M.P., Leczenie operacyjne przerzutów do wątroby, „Nowa Medycyna”, 4/1999, 1999, s. 32-37 [dostęp 2024-05-07] .

doi.org

dx.doi.org

Vincent T.V.T. DeVita Vincent T.V.T., EdwardE. Chu EdwardE., A History of Cancer Chemotherapy, „Cancer Research”, 68 (21), 2008, s. 8643–8653, DOI: 10.1158/0008-5472.CAN-07-6611, PMID: 18974103 [dostęp 2024-04-22] (ang.).
KjK. Williams KjK., The introduction of ‘chemotherapy’ using arsphenamine – the first magic bullet, „Journal of the Royal Society of Medicine”, 102 (8), 2009, s. 343–348, DOI: 10.1258/jrsm.2009.09k036, PMID: 19679737, PMCID: PMC2726818 [dostęp 2024-04-22] (ang.).
E.B.E.B. Krumbhaar E.B.E.B., Role of the blood and the bone marrow in certain forms of gas poisoning I. Peripheral blood changes and their significance, „Journal of the American Medical Association”, 72 (1), 1919, s. 39, DOI: 10.1001/jama.1919.26110010018009f [dostęp 2024-04-22] (ang.).
Louis S.L.S. Goodman Louis S.L.S., Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin’s disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders, „Journal of the American Medical Association”, 132 (3), 1946, s. 126, DOI: 10.1001/jama.1946.02870380008004, PMID: 20997191 [dostęp 2024-04-22] (ang.).
SidneyS. Farber SidneyS. i inni, Temporary Remissions in Acute Leukemia in Children Produced by Folic Acid Antagonist, 4-Aminopteroyl-Glutamic Acid (Aminopterin), „The New England Journal of Medicine”, 238 (23), 1948, s. 787–793, DOI: 10.1056/NEJM194806032382301, PMID: 18860765 [dostęp 2024-04-22] (ang.).
Denis R.D.R. Miller Denis R.D.R., A tribute to Sidney Farber – the father of modern chemotherapy, „British Journal of Haematology”, 134 (1), 2006, s. 20–26, DOI: 10.1111/j.1365-2141.2006.06119.x, PMID: 16803563 [dostęp 2024-04-22] (ang.).
CharlesCh. Heidelberger CharlesCh. i inni, Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory Compounds, „Nature”, 179 (4561), 1957, s. 663–666, DOI: 10.1038/179663a0, PMID: 13418758 [dostęp 2024-04-22] (ang.).
George H.G.H. Hitchings George H.G.H., Gertrude B.G.B. Elion Gertrude B.G.B., The chemistry and biochemistry of purine analogs, „Annals of the New York Academy of Sciences”, 60 (2), 1954, s. 195–199, DOI: 10.1111/j.1749-6632.1954.tb40008.x, PMID: 14350523 [dostęp 2024-04-22] (ang.).
R.R. Hertz R.R., M.C.M.C. Li M.C.M.C., D.B.D.B. Spencer D.B.D.B., Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma, „Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine”, 93 (2), 1956, s. 361–366, DOI: 10.3181/00379727-93-22757, PMID: 13379512 [dostęp 2024-04-22] (ang.).
E.E. Frei E.E. i inni, The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia, „Blood”, 26 (5), 1965, s. 642–656, DOI: 10.1182/blood.V26.5.642.642, PMID: 5321112 [dostęp 2024-04-22] (ang.).
BarnettB. Rosenberg BarnettB., Loretta VanL.V. Camp Loretta VanL.V., ThomasT. Krigas ThomasT., Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode, „Nature”, 205 (4972), 1965, s. 698–699, DOI: 10.1038/205698a0, PMID: 14287410 [dostęp 2024-04-22] (ang.).
G.G. Damia G.G., M.M. D'Incalci M.M., Mechanisms of resistance to alkylating agents, „Cytotechnology”, 27 (1/3), 1998, s. 165–173, DOI: 10.1023/A:1008060720608, PMID: 19002790, PMCID: PMC3449574 [dostęp 2024-04-22] (ang.).
Christopher W.Ch.W. Carreras Christopher W.Ch.W., Daniel V.D.V. Santi Daniel V.D.V., The catalytic mechanism and structure of thymidylate synthase, „Annual Review of Biochemistry”, 64 (1), 1995, s. 721–762, DOI: 10.1146/annurev.bi.64.070195.003445, PMID: 7574499 [dostęp 2024-04-22] (ang.).
ValérieV. Ganansia-Leymarie ValérieV. i inni, Signal transduction pathways of taxanes-induced apoptosis, „Current Medicinal Chemistry. Anti-Cancer Agents”, 3 (4), 2003, s. 291–306, DOI: 10.2174/1568011033482422, PMID: 12769774 [dostęp 2024-04-22] (ang.).
YiY. Huang YiY. i inni, Regulation of Vinca alkaloid-induced apoptosis by NF-kappaB/IkappaB pathway in human tumor cells, „Molecular Cancer Therapeutics”, 3 (3), 2004, s. 271–277, DOI: 10.1158/1535-7163.271.3.3, PMID: 15026547 [dostęp 2024-04-22] (ang.).
Manuel M.M.M. Paz Manuel M.M.M. i inni, A New Mechanism of Action for the Anticancer Drug Mitomycin C: Mechanism-Based Inhibition of Thioredoxin Reductase, „Chemical Research in Toxicology”, 25 (7), 2012, s. 1502–1511, DOI: 10.1021/tx3002065, PMID: 22694104 [dostęp 2024-04-22] (ang.).
M.M. Tomasz M.M., Mitomycin C: small, fast and deadly (but very selective), „Chemistry & Biology”, 2 (9), 1995, s. 575–579, DOI: 10.1016/1074-5521(95)90120-5, PMID: 9383461 [dostęp 2024-04-22] (ang.).
G.G. Makin G.G., J.A.J.A. Hickman J.A.J.A., Apoptosis and cancer chemotherapy, „Cell and Tissue Research”, 301 (1), 2000, s. 143–152, DOI: 10.1007/s004419900160, PMID: 10928287 [dostęp 2024-04-22] (ang.).
Pippa G.P.G. Corrie Pippa G.P.G., Cytotoxic chemotherapy: clinical aspects, „Medicine”, 36 (1), 2008, s. 24–28, DOI: 10.1016/j.mpmed.2007.10.012 [dostęp 2024-04-22] (ang.).
Richard J.R.J. Epstein Richard J.R.J., Maintenance Therapy to Suppress Micrometastasis: The New Challenge for Adjuvant Cancer Treatment, „Clinical Cancer Research”, 11 (15), 2005, s. 5337–5341, DOI: 10.1158/1078-0432.CCR-05-0437, PMID: 16061845 [dostęp 2024-04-22] (ang.).
D.A.D.A. Eichenauer D.A.D.A. i inni, Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, „Annals of Oncology”, 25, 2014, iii70–iii75, DOI: 10.1093/annonc/mdu181, PMID: 25185243 [dostęp 2024-04-22] (ang.).
A.A. Okines A.A. i inni, Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, „Annals of Oncology”, 21, 2010, v50–v54, DOI: 10.1093/annonc/mdq164, PMID: 20555102 [dostęp 2024-04-22] (ang.).
E. VanE.V. Cutsem E. VanE.V. i inni, Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, „Annals of Oncology”, 25, 2014, iii1–iii9, DOI: 10.1093/annonc/mdu260, PMID: 25190710 [dostęp 2024-04-22] (ang.).
M.M. Früh M.M. i inni, Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, „Annals of Oncology”, 24, 2013, vi99–vi105, DOI: 10.1093/annonc/mdt178, PMID: 23813929 [dostęp 2024-04-22] (ang.).
M.M. Reck M.M. i inni, Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, „Annals of Oncology”, 25, 2014, iii27–iii39, DOI: 10.1093/annonc/mdu199, PMID: 25115305 [dostęp 2024-04-22] (ang.).
Sing YuS.Y. Moorcraft Sing YuS.Y., Daniel L.Y.D.L.Y. Lee Daniel L.Y.D.L.Y., DavidD. Cunningham DavidD., Clinical Problems in Oncology: A Practical Guide to Management, DOI: 10.1002/9781118673768.app1, ISBN 978-1-118-67382-9 .
V.V. Grégoire V.V. i inni, Squamous cell carcinoma of the head and neck: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up, „Annals of Oncology”, 21, 2010, v184–v186, DOI: 10.1093/annonc/mdq185, PMID: 20555077 [dostęp 2024-04-22] (ang.).
N.N. Kiyota N.N. i inni, Systemic Chemotherapy with Cisplatin Plus 5-FU (PF) for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN): Efficacy and Safety of a Lower Dose of PF (80/800) at a Single Institution in Japan, „Japanese Journal of Clinical Oncology”, 39 (4), 2009, s. 225–230, DOI: 10.1093/jjco/hyp002, PMID: 19211574 [dostęp 2024-04-22] (ang.).
E.E. Senkus E.E. i inni, Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, „Annals of Oncology”, 24, 2013, vi7–vi23, DOI: 10.1093/annonc/mdt284, PMID: 23970019 [dostęp 2024-04-22] (ang.).
William J.W.J. Gradishar William J.W.J. i inni, Breast cancer version 3.2014, „Journal of the National Comprehensive Cancer Network”, 12 (4), 2014, s. 542–590, DOI: 10.6004/jnccn.2014.0058, PMID: 24717572 [dostęp 2024-04-22] (ang.).
J.A.J.A. Ledermann J.A.J.A. i inni, Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, „Annals of Oncology”, 24, 2013, vi24–vi32, DOI: 10.1093/annonc/mdt333, PMID: 24078660 [dostęp 2024-04-22] (ang.).
Gary H.G.H. Lyman Gary H.G.H., Impact of chemotherapy dose intensity on cancer patient outcomes, „Journal of the National Comprehensive Cancer Network”, 7 (1), 2009, s. 99–108, DOI: 10.6004/jnccn.2009.0009, PMID: 19176210 [dostęp 2024-04-22] (ang.).
Marc L.M.L. Citron Marc L.M.L., Dose-Dense Chemotherapy: Principles, Clinical Results and Future Perspectives, „Breast Care”, 3 (4), 2008, s. 251–255, DOI: 10.1159/000148914, PMID: 21076605, PMCID: PMC2974980 [dostęp 2024-04-22] (ang.).
D.J.D.J. Dodwell D.J.D.J., H.H. Gurney H.H., N.N. Thatcher N.N., Dose intensity in cancer chemotherapy, „British Journal of Cancer”, 61 (6), 1990, s. 789–794, DOI: 10.1038/bjc.1990.178, PMID: 2164831, PMCID: PMC1971684 [dostęp 2024-04-22] (ang.).
ErickE. Gamelin ErickE. i inni, Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal Cancer, „Journal of Clinical Oncology”, 26 (13), 2008, s. 2099–2105, DOI: 10.1200/JCO.2007.13.3934, PMID: 18445839 [dostęp 2024-04-22] (ang.).
OlivierO. Capitain OlivierO. i inni, Individual Fluorouracil Dose Adjustment in FOLFOX Based on Pharmacokinetic Follow-Up Compared With Conventional Body-Area-Surface Dosing: A Phase II, Proof-of-Concept Study, „Clinical Colorectal Cancer”, 11 (4), 2012, s. 263–267, DOI: 10.1016/j.clcc.2012.05.004, PMID: 22683364 [dostęp 2024-04-22] (ang.).
S.A.S.A. Kaestner S.A.S.A., G.J.G.J. Sewell G.J.G.J., Chemotherapy Dosing Part I: Scientific Basis for Current Practice and Use of Body Surface Area, „Clinical Oncology”, 19 (1), 2007, s. 23–37, DOI: 10.1016/j.clon.2006.10.010, PMID: 17305252 [dostęp 2024-04-22] (ang.).
Jan H.J.H. Beumer Jan H.J.H., EdwardE. Chu EdwardE., Salvatore J.S.J. Salamone Salvatore J.S.J., Body-Surface Area–Based Chemotherapy Dosing: Appropriate in the 21st Century?, „Journal of Clinical Oncology”, 30 (31), 2012, s. 3896–3897, DOI: 10.1200/JCO.2012.44.2863, PMID: 22965963 [dostęp 2024-04-22] (ang.).
Sharyn D.S.D. Baker Sharyn D.S.D. i inni, Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001, „Journal of the National Cancer Institute”, 94 (24), 2002, s. 1883–1888, DOI: 10.1093/jnci/94.24.1883, PMID: 12488482 [dostęp 2024-04-22] (ang.).
A.A. Felici A.A., J.J. Verweij J.J., A.A. Sparreboom A.A., Dosing strategies for anticancer drugs: the good, the bad and body-surface area, „European Journal of Cancer”, 38 (13), 2002, s. 1677–1684, DOI: 10.1016/s0959-8049(02)00151-x, PMID: 12175683 [dostęp 2024-04-22] (ang.).
M.AM.A. Rudek M.AM.A. i inni, Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy, „European Journal of Cancer”, 40 (8), 2004, s. 1170–1178, DOI: 10.1016/j.ejca.2003.12.026, PMID: 15110880 [dostęp 2024-04-22] (ang.).
HH. Gurney HH., How to calculate the dose of chemotherapy, „British Journal of Cancer”, 86 (8), 2002, s. 1297–1302, DOI: 10.1038/sj.bjc.6600139, PMID: 11953888, PMCID: PMC2375356 [dostęp 2024-04-22] (ang.).
Rodney J.R.J. Hunter Rodney J.R.J. i inni, Dosing chemotherapy in obese patients: Actual versus assigned body surface area (BSA), „Cancer Treatment Reviews”, 35 (1), 2009, s. 69–78, DOI: 10.1016/j.ctrv.2008.07.005, PMID: 18922643 [dostęp 2024-04-22] (ang.).
Jennifer J.J.J. Griggs Jennifer J.J.J. i inni, Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline, „Journal of Clinical Oncology”, 30 (13), 2012, s. 1553–1561, DOI: 10.1200/JCO.2011.39.9436, PMID: 22473167 [dostęp 2024-04-22] (ang.).
Rajesh R.R.R. Kaldate Rajesh R.R.R. i inni, Modeling the 5-Fluorouracil Area Under the Curve Versus Dose Relationship to Develop a Pharmacokinetic Dosing Algorithm for Colorectal Cancer Patients Receiving FOLFOX6, „The Oncologist”, 17 (3), 2012, s. 296–302, DOI: 10.1634/theoncologist.2011-0357, PMID: 22382460, PMCID: PMC3316912 [dostęp 2024-04-22] (ang.).
M. WasifM.W. Saif M. WasifM.W. i inni, Pharmacokinetically Guided Dose Adjustment of 5-Fluorouracil: A Rational Approach to Improving Therapeutic Outcomes, „Journal of the National Cancer Institute”, 101 (22), 2009, s. 1543–1552, DOI: 10.1093/jnci/djp328, PMID: 19841331 [dostęp 2024-04-22] (ang.).
Y.Y.Y.Y. Hon Y.Y.Y.Y., W.E.W.E. Evans W.E.W.E., Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach, „Clinical Chemistry”, 44 (2), 1998, s. 388–400, DOI: 10.1093/clinchem/44.2.388, PMID: 9474050 [dostęp 2024-04-22] (ang.).
Milly E deM.E. Jonge Milly E deM.E. i inni, Individualised Cancer Chemotherapy: Strategies and Performance of Prospective Studies on Therapeutic Drug Monitoring with Dose Adaptation: A Review, „Clinical Pharmacokinetics”, 44 (2), 2005, s. 147–173, DOI: 10.2165/00003088-200544020-00002, PMID: 15656695 [dostęp 2024-04-22] (ang.).
E.R.E.R. Sigurdson E.R.E.R. i inni, Tumor and liver drug uptake following hepatic artery and portal vein infusion, „Journal of Clinical Oncology”, 5 (11), 1987, s. 1836–1840, DOI: 10.1200/JCO.1987.5.11.1836, PMID: 3681370 [dostęp 2024-04-24] (ang.).
D.C.D.C. Hohn D.C.D.C. i inni, A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial., „Journal of Clinical Oncology”, 7 (11), 1989, s. 1646–1654, DOI: 10.1200/JCO.1989.7.11.1646, PMID: 2530317 [dostęp 2024-04-24] (ang.).
NancyN. Kemeny NancyN., Intrahepatic or Systemic Infusion of Fluorodeoxyuridine in Patients with Liver Metastases from Colorectal Carcinoma: A Randomized Trial, „Annals of Internal Medicine”, 107 (4), 1987, s. 459, DOI: 10.7326/0003-4819-107-4-459, PMID: 2957943 [dostęp 2024-04-24] (ang.).
Alfred E.A.E. Chang Alfred E.A.E. i inni, A Prospective Randomized Trial of Regional Versus Systemic Continuous 5-Fluorodeoxyuridine Chemotherapy in the Treatment of Colorectal Liver Metastases:, „Annals of Surgery”, 206 (6), 1987, s. 685–693, DOI: 10.1097/00000658-198712000-00001, PMID: 2961314, PMCID: PMC1493315 [dostęp 2024-04-24] (ang.).
NancyN. Kemeny NancyN. i inni, Phase I Trial of Systemic Oxaliplatin Combination Chemotherapy With Hepatic Arterial Infusion in Patients With Unresectable Liver Metastases From Colorectal Cancer, „Journal of Clinical Oncology”, 23 (22), 2005, s. 4888–4896, DOI: 10.1200/JCO.2005.07.100, PMID: 16009951 [dostęp 2024-04-24] (ang.).
NancyN. Kemeny NancyN. i inni, Hepatic Arterial Infusion of Chemotherapy after Resection of Hepatic Metastases from Colorectal Cancer, „The New England Journal of Medicine”, 341 (27), 1999, s. 2039–2048, DOI: 10.1056/NEJM199912303412702, PMID: 10615075 [dostęp 2024-04-24] (ang.).
M. MargaretM.M. Kemeny M. MargaretM.M. i inni, Combined-Modality Treatment for Resectable Metastatic Colorectal Carcinoma to the Liver: Surgical Resection of Hepatic Metastases in Combination With Continuous Infusion of Chemotherapy—An Intergroup Study, „Journal of Clinical Oncology”, 20 (6), 2002, s. 1499–1505, DOI: 10.1200/JCO.2002.20.6.1499, PMID: 11896097 [dostęp 2024-04-24] (ang.).
SergioS. Frustaci SergioS. i inni, Intra-arterial continuous infusion of cis-diamminedichloroplatinum in untreated head and neck cancer patients, „Cancer”, 57 (6), 1986, s. 1118–1123, DOI: 10.1002/1097-0142(19860315)57:6<1118::AID-CNCR2820570610>3.0.CO;2-5, PMID: 3943035 [dostęp 2024-04-24] (ang.).
J EJ.E. Mortimer J EJ.E. i inni, Feasibility and efficacy of weekly intraarterial cisplatin in locally advanced (stage III and IV) head and neck cancers., „Journal of Clinical Oncology”, 6 (6), 1988, s. 969–975, DOI: 10.1200/JCO.1988.6.6.969, PMID: 3373266 [dostęp 2024-04-24] (ang.).
LarsL. Podleska LarsL. i inni, Drug dosage in isolated limb perfusion: evaluation of a limb volume model for extremity volume calculation, „World Journal of Surgical Oncology”, 12 (1), 2014, s. 81, DOI: 10.1186/1477-7819-12-81, PMID: 24684972, PMCID: PMC3994217 [dostęp 2024-04-24] (ang.).
Tim D.T.D. Pencavel Tim D.T.D. i inni, Isolated limb perfusion with melphalan, tumour necrosis factor‐alpha and oncolytic vaccinia virus improves tumour targeting and prolongs survival in a rat model of advanced extremity sarcoma, „International Journal of Cancer”, 136 (4), 2015, s. 965–976, DOI: 10.1002/ijc.29059, PMID: 24978211 [dostęp 2024-04-24] (ang.).
DavidD. Moreno-Ramirez DavidD. i inni, Isolated Limb Perfusion for Malignant Melanoma: Systematic Review on Effectiveness and Safety, „The Oncologist”, 15 (4), 2010, s. 416–427, DOI: 10.1634/theoncologist.2009-0325, PMID: 20348274, PMCID: PMC3227960 [dostęp 2024-04-24] (ang.).
J.M.H.J.M.H. Hendriks J.M.H.J.M.H., P.E.Y. VanP.E.Y.V. Schil P.E.Y. VanP.E.Y.V., Isolated lung perfusion for the treatment of pulmonary metastases, „Surgical Oncology”, 7 (1-2), 1998, s. 59–63, DOI: 10.1016/S0960-7404(98)00028-0, PMID: 10421507 [dostęp 2024-04-24] (ang.).
Willem A. denW.A. Hengst Willem A. denW.A. i inni, Phase II Multicenter Clinical Trial of Pulmonary Metastasectomy and Isolated Lung Perfusion with Melphalan in Patients with Resectable Lung Metastases, „Journal of Thoracic Oncology”, 9 (10), 2014, s. 1547–1553, DOI: 10.1097/JTO.0000000000000279, PMID: 25105436 [dostęp 2024-04-24] (ang.).
Pierre-BenoitP.B. Pagès Pierre-BenoitP.B. i inni, Isolated Lung Perfusion as an Adjuvant Treatment of Colorectal Cancer Lung Metastases: A Preclinical Study in a Pig Model, „PLoS ONE”, 8 (3), 2013, e59485, DOI: 10.1371/journal.pone.0059485, PMID: 23527205, PMCID: PMC3601104 [dostęp 2024-04-24] (ang.).
W.A. DenW.A.D. Hengst W.A. DenW.A.D. i inni, Selective pulmonary artery perfusion with melphalan is equal to isolated lung perfusion but superior to intravenous melphalan for the treatment of sarcoma lung metastases in a rodent model, „European Journal of Cardio-Thoracic Surgery”, 42 (2), 2012, s. 341–347, DOI: 10.1093/ejcts/ezs017, PMID: 22345285 [dostęp 2024-04-24] (ang.).
MM. Markman MM. i inni, Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin., „Journal of Clinical Oncology”, 9 (10), 1991, s. 1801–1805, DOI: 10.1200/JCO.1991.9.10.1801, PMID: 1919630 [dostęp 2024-04-24] (ang.).
FredF. Shapiro FredF. i inni, High-Intensity Intravenous Cyclophosphamide and Cisplatin, Interim Surgical Debulking, and Intraperitoneal Cisplatin in Advanced Ovarian Carcinoma: A Pilot Trial with Ten-Year Follow-up, „Gynecologic Oncology”, 67 (1), 1997, s. 39–45, DOI: 10.1006/gyno.1997.4821, PMID: 9345354 [dostęp 2024-04-24] (ang.).
Helen J.H.J. Mackay Helen J.H.J. i inni, Phase II/III Study of Intraperitoneal Chemotherapy after Neoadjuvant Chemotherapy for Ovarian Cancer: NCIC CTG OV.21, „Current Oncology”, 18 (2), 2011, s. 84–90, DOI: 10.3747/co.v18i2.725, PMID: 21505599, PMCID: PMC3070707 [dostęp 2024-04-24] (ang.).
DD. Kelsen DD. i inni, Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil., „Journal of Clinical Oncology”, 14 (6), 1996, s. 1818–1828, DOI: 10.1200/JCO.1996.14.6.1818, PMID: 8656250 [dostęp 2024-04-24] (ang.).
O TO.T. Atiq O TO.T. i inni, Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer., „Journal of Clinical Oncology”, 11 (3), 1993, s. 425–433, DOI: 10.1200/JCO.1993.11.3.425, PMID: 8445416 [dostęp 2024-04-24] (ang.).
Andrew L.A.L. Feldman Andrew L.A.L. i inni, Analysis of Factors Associated With Outcome in Patients With Malignant Peritoneal Mesothelioma Undergoing Surgical Debulking and Intraperitoneal Chemotherapy, „Journal of Clinical Oncology”, 21 (24), 2003, s. 4560–4567, DOI: 10.1200/JCO.2003.04.150, PMID: 14673042 [dostęp 2024-04-24] (ang.).
MaurieM. Markman MaurieM., DavidD. Kelsen DavidD., Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma, „Journal of Cancer Research and Clinical Oncology”, 118 (7), 1992, s. 547–550, DOI: 10.1007/BF01225271, PMID: 1624547 [dostęp 2024-04-24] (ang.).
PeterP. Dyck PeterP., Lumbar reservoir for intrathecal chemotherapy, „Cancer”, 55 (12), 1985, s. 2771–2773, DOI: 10.1002/1097-0142(19850615)55:12<2771::AID-CNCR2820551208>3.0.CO;2-I, PMID: 3838918 [dostęp 2024-04-24] (ang.).
Eugenie A.M.T.E.A.M.T. Obbens Eugenie A.M.T.E.A.M.T. i inni, Ommaya reservoirs in 387 cancer patients: A 15‐year experience, „Neurology”, 35 (9), 1985, s. 1274–1274, DOI: 10.1212/WNL.35.9.1274, PMID: 3839573 [dostęp 2024-04-24] (ang.).
Yok-LamY.L. Kwong Yok-LamY.L., Dominic Y.M.D.Y.M. Yeung Dominic Y.M.D.Y.M., Joyce C.W.J.C.W. Chan Joyce C.W.J.C.W., Intrathecal chemotherapy for hematologic malignancies: drugs and toxicities, „Annals of Hematology”, 88 (3), 2009, s. 193–201, DOI: 10.1007/s00277-008-0645-y, PMID: 19050889 [dostęp 2024-04-24] (ang.).
N.N. Gokbuget N.N. i inni, Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma, „Haematologica”, 96 (2), 2011, s. 238–244, DOI: 10.3324/haematol.2010.028092, PMID: 20952517, PMCID: PMC3031691 [dostęp 2024-04-24] (ang.).
D.D. Martinez-Cuadron D.D. i inni, Central nervous system involvement at first relapse in patients with acute myeloid leukemia, „Haematologica”, 96 (9), 2011, s. 1375–1379, DOI: 10.3324/haematol.2011.042960, PMID: 21565904, PMCID: PMC3166110 [dostęp 2024-04-30] (ang.).
Koen vanK. Besien Koen vanK. i inni, Risk Factors, Treatment, and Outcome of Central Nervous System Recurrence in Adults With Intermediate-Grade and Immunoblastic Lymphoma, „Blood”, 91 (4), 1998, s. 1178–1184, DOI: 10.1182/blood.V91.4.1178, PMID: 9454747 [dostęp 2024-04-30] (ang.).
Ching-HonCh.H. Pui Ching-HonCh.H., EckhardE. Thiel EckhardE., Central Nervous System Disease in Hematologic Malignancies: Historical Perspective and Practical Applications, „Seminars in Oncology”, 36, 2009, S2–S16, DOI: 10.1053/j.seminoncol.2009.05.002, PMID: 19660680, PMCID: PMC2805279 [dostęp 2024-04-30] (ang.).
Lisa M.L.M. DeAngelis Lisa M.L.M. i inni, Combination Chemotherapy and Radiotherapy for Primary Central Nervous System Lymphoma: Radiation Therapy Oncology Group Study 93-10, „Journal of Clinical Oncology”, 20 (24), 2002, s. 4643–4648, DOI: 10.1200/JCO.2002.11.013, PMID: 12488408 [dostęp 2024-04-30] (ang.).
SeiichiS. Yoshida SeiichiS., KenK. Morii KenK., Intrathecal chemotherapy for patients with meningeal carcinomatosis, „Surgical Neurology”, 63 (1), 2005, s. 52–55, DOI: 10.1016/j.surneu.2004.06.011, PMID: 15639526 [dostęp 2024-04-30] (ang.).
Jin HyunJ.H. Park Jin HyunJ.H. i inni, Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era, „Lung Cancer”, 76 (3), 2012, s. 387–392, DOI: 10.1016/j.lungcan.2011.11.022, PMID: 22186628 [dostęp 2024-04-30] (ang.).
KatelynK. Chitwood KatelynK., JeremyJ. Etzkorn JeremyJ., GeorgeG. Cohen GeorgeG., Topical and Intralesional Treatment of Nonmelanoma Skin Cancer: Efficacy and Cost Comparisons, „Dermatologic Surgery”, 39 (9), 2013, s. 1306–1316, DOI: 10.1111/dsu.12300, PMID: 23915332 [dostęp 2024-04-30] (ang.).
S.W.S.W. Lowe S.W.S.W. i inni, p53-dependent apoptosis modulates the cytotoxicity of anticancer agents, „Cell”, 74 (6), 1993, s. 957–967, DOI: 10.1016/0092-8674(93)90719-7, PMID: 8402885 [dostęp 2024-04-30] (ang.).
C.C. Dumontet C.C., B.I.B.I. Sikic B.I.B.I., Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death, „Journal of Clinical Oncology”, 17 (3), 1999, s. 1061–1070, DOI: 10.1200/JCO.1999.17.3.1061, PMID: 10071301 [dostęp 2024-04-30] (ang.).
A.B.A.B. Pardee A.B.A.B., Growth dysregulation in cancer cells, „Advances in Cancer Research”, 65, 1994, s. 213–228, DOI: 10.1016/s0065-230x(08)60070-6, PMID: 7879668 [dostęp 2024-04-30] (ang.).
Y.A.Y.A. Luqmani Y.A.Y.A., Mechanisms of drug resistance in cancer chemotherapy, „Medical Principles and Practice”, 14 Suppl 1, 2005, s. 35–48, DOI: 10.1159/000086183, PMID: 16103712 [dostęp 2024-04-30] (ang.).
SarojS. Vadhan-Raj SarojS., Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents, „Seminars in Hematology”, 46 (1 Suppl 2), 2009, S26–32, DOI: 10.1053/j.seminhematol.2008.12.007, PMID: 19245931 [dostęp 2024-04-30] (ang.).
HeinzH. Ludwig HeinzH. i inni, The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients, „European Journal of Cancer”, 40 (15), 2004, s. 2293–2306, DOI: 10.1016/j.ejca.2004.06.019, PMID: 15454256 [dostęp 2024-04-30] (ang.).
Patricia K.P.K. Corey-Lisle Patricia K.P.K. i inni, Transfusions and patient burden in chemotherapy-induced anaemia in France, „Therapeutic Advances in Medical Oncology”, 6 (4), 2014, s. 146–153, DOI: 10.1177/1758834014534515, PMID: 25057301, PMCID: PMC4107713 [dostęp 2024-04-30] (ang.).
J.E.J.E. Groopman J.E.J.E., L.M.L.M. Itri L.M.L.M., Chemotherapy-induced anemia in adults: incidence and treatment, „Journal of the National Cancer Institute”, 91 (19), 1999, s. 1616–1634, DOI: 10.1093/jnci/91.19.1616, PMID: 10511589 [dostęp 2024-04-30] (ang.).
George M.G.M. Rodgers George M.G.M. i inni, Cancer- and chemotherapy-induced anemia, „Journal of the National Comprehensive Cancer Network”, 6 (6), 2008, s. 536–564, DOI: 10.6004/jnccn.2008.0042, PMID: 18597709 [dostęp 2024-04-30] (ang.).
LianaL. Scialdone LianaL., Overview of supportive care in patients receiving chemotherapy: antiemetics, pain management, anemia, and neutropenia, „Journal of Pharmacy Practice”, 25 (2), 2012, s. 209–221, DOI: 10.1177/0897190011431631, PMID: 22307093 [dostęp 2024-04-30] (ang.).
JohanJ. Vansteenkiste JohanJ. i inni, Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy, „Journal of the National Cancer Institute”, 94 (16), 2002, s. 1211–1220, DOI: 10.1093/jnci/94.16.1211, PMID: 12189224 [dostęp 2024-04-30] (ang.).
MichaelM. Hedenus MichaelM. i inni, Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study, „British Journal of Haematology”, 122 (3), 2003, s. 394–403, DOI: 10.1046/j.1365-2141.2003.04448.x, PMID: 12877666 [dostęp 2024-04-30] (ang.).
L.L. Gomez L.L., R.R. Martino R.R., K.V.K.V. Rolston K.V.K.V., Neutropenic enterocolitis: spectrum of the disease and comparison of definite and possible cases, „Clinical Infectious Diseases”, 27 (4), 1998, s. 695–699, DOI: 10.1086/514946, PMID: 9798018 [dostęp 2024-04-30] (ang.).
H. Jervoise N.H.J.N. Andreyev H. Jervoise N.H.J.N. i inni, Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer, „Gut”, 61 (2), 2012, s. 179–192, DOI: 10.1136/gutjnl-2011-300563, PMID: 22057051, PMCID: PMC3245898 [dostęp 2024-04-30] (ang.).
ZhiyongZ. Li ZhiyongZ. i inni, Colitis in patients with breast carcinoma treated with taxane-based chemotherapy, „Cancer”, 101 (7), 2004, s. 1508–1513, DOI: 10.1002/cncr.20546, PMID: 15378497 [dostęp 2024-04-30] (ang.).
HarmeetH. Kaur HarmeetH. i inni, Radiologic findings in taxane induced colitis, „European Journal of Radiology”, 66 (1), 2008, s. 75–78, DOI: 10.1016/j.ejrad.2007.04.024, PMID: 17553645 [dostęp 2024-04-30] (ang.).
ElisabethE. Schellhaas ElisabethE. i inni, Bowel perforation in non-small cell lung cancer after bevacizumab therapy, „Investigational New Drugs”, 27 (2), 2009, s. 184–187, DOI: 10.1007/s10637-008-9162-z, PMID: 18665327 [dostęp 2024-04-30] (ang.).
Kimberly E.K.E. Beck Kimberly E.K.E. i inni, Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4, „Journal of Clinical Oncology”, 24 (15), 2006, s. 2283–2289, DOI: 10.1200/JCO.2005.04.5716, PMID: 16710025, PMCID: PMC2140223 [dostęp 2024-04-30] (ang.).
Julian H.J.H. Slade Julian H.J.H. i inni, Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury, „Clinical Colorectal Cancer”, 8 (4), 2009, s. 225–230, DOI: 10.3816/CCC.2009.n.038, PMID: 19822514 [dostęp 2024-04-30] (ang.).
A.Y.A.Y. Lee A.Y.A.Y., M.N.M.N. Levine M.N.M.N., The thrombophilic state induced by therapeutic agents in the cancer patient, „Seminars in Thrombosis and Hemostasis”, 25 (2), 1999, s. 137–145, DOI: 10.1055/s-2007-994915, PMID: 10357081 [dostęp 2024-04-30] (ang.).
Doranne L.D.L. Hilarius Doranne L.D.L. i inni, Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study, „Supportive Care in Cancer”, 20 (1), 2012, s. 107–117, DOI: 10.1007/s00520-010-1073-9, PMID: 21258948, PMCID: PMC3223596 [dostęp 2024-04-30] (ang.).
LorenzoL. Cohen LorenzoL. i inni, Chemotherapy-induced nausea and vomiting—incidence and impact on patient quality of life at community oncology settings, „Supportive Care in Cancer”, 15 (5), 2007, s. 497–503, DOI: 10.1007/s00520-006-0173-z, PMID: 17103197 [dostęp 2024-05-02] (ang.).
CaroleC. Farrell CaroleC. i inni, The impact of chemotherapy-related nausea on patients' nutritional status, psychological distress and quality of life, „Supportive Care in Cancer”, 21 (1), 2013, s. 59–66, DOI: 10.1007/s00520-012-1493-9, PMID: 22610269 [dostęp 2024-05-02] (ang.).
BrigitteB. Bloechl-Daum BrigitteB. i inni, Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment, „Journal of Clinical Oncology”, 24 (27), 2006, s. 4472–4478, DOI: 10.1200/JCO.2006.05.6382, PMID: 16983116 [dostęp 2024-05-02] (ang.).
S.M.S.M. Fox S.M.S.M. i inni, Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy, „Journal of Clinical Oncology”, 11 (12), 1993, s. 2391–2395, DOI: 10.1200/JCO.1993.11.12.2391, PMID: 8246028 [dostęp 2024-05-02] (ang.).
KarinK. Jordan KarinK., ChristophCh. Sippel ChristophCh., Hans-JoachimH.J. Schmoll Hans-JoachimH.J., Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations, „The Oncologist”, 12 (9), 2007, s. 1143–1150, DOI: 10.1634/theoncologist.12-9-1143, PMID: 17914084 [dostęp 2024-05-02] (ang.).
EthanE. Basch EthanE. i inni, Antiemetics: american society of clinical oncology clinical practice guideline update, „Journal of Oncology Practice”, 7 (6), 2011, s. 395–398, DOI: 10.1200/JOP.2011.000397, PMID: 22379425, PMCID: PMC3219469 [dostęp 2024-05-02] (ang.).
F.F. Roila F.F. i inni, Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference, „Annals of Oncology”, 17 (1), 2006, s. 20–28, DOI: 10.1093/annonc/mdj078, PMID: 16314401 [dostęp 2024-05-02] (ang.).
Marwan M.M.M. Refaat Marwan M.M.M., William E.W.E. Katz William E.W.E., Neoplastic pericardial effusion, „Clinical Cardiology”, 34 (10), 2011, s. 593–598, DOI: 10.1002/clc.20936, PMID: 21928406, PMCID: PMC6652358 [dostęp 2024-05-05] (ang.).
Hamilton S.H.S. Gillespie Hamilton S.H.S., Christopher J.Ch.J. McGann Christopher J.Ch.J., Brent D.B.D. Wilson Brent D.B.D., Noninvasive diagnosis of chemotherapy related cardiotoxicity, „Current Cardiology Reviews”, 7 (4), 2011, s. 234–244, DOI: 10.2174/157340311799960672, PMID: 22758624, PMCID: PMC3322441 [dostęp 2024-05-05] (ang.).
AdrianaA. Albini AdrianaA. i inni, Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention, „Journal of the National Cancer Institute”, 102 (1), 2010, s. 14–25, DOI: 10.1093/jnci/djp440, PMID: 20007921, PMCID: PMC2802286 [dostęp 2024-05-05] (ang.).
V.B.V.B. Pai V.B.V.B., M.C.M.C. Nahata M.C.M.C., Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention, „Drug Safety”, 22 (4), 2000, s. 263–302, DOI: 10.2165/00002018-200022040-00002, PMID: 10789823 [dostęp 2024-05-05] (ang.).
AxelA. Schlitt AxelA. i inni, Cardiotoxicity and oncological treatments, „Deutsches Arzteblatt International”, 111 (10), 2014, s. 161–168, DOI: 10.3238/arztebl.2014.0161, PMID: 24666651, PMCID: PMC3971565 [dostęp 2024-05-05] (ang.).
R.R. Jeyaseelan R.R. i inni, Molecular mechanisms of doxorubicin-induced cardiomyopathy. Selective suppression of Reiske iron-sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes, „Journal of Biological Chemistry”, 272 (9), 1997, s. 5828–5832, DOI: 10.1074/jbc.272.9.5828, PMID: 9038198 [dostęp 2024-05-05] (ang.).
J.H.J.H. Doroshow J.H.J.H., G.Y.G.Y. Locker G.Y.G.Y., C.E.C.E. Myers C.E.C.E., Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin, „The Journal of Clinical Investigation”, 65 (1), 1980, s. 128–135, DOI: 10.1172/JCI109642, PMID: 7350193, PMCID: PMC371347 [dostęp 2024-05-05] (ang.).
DirkD. Lebrecht DirkD. i inni, Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy, „Circulation”, 108 (19), 2003, s. 2423–2429, DOI: 10.1161/01.CIR.0000093196.59829.DF, PMID: 14568902 [dostęp 2024-05-05] (ang.).
Karlijn A.K.A. Wouters Karlijn A.K.A. i inni, Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies, „British Journal of Haematology”, 131 (5), 2005, s. 561–578, DOI: 10.1111/j.1365-2141.2005.05759.x, PMID: 16351632 [dostęp 2024-05-05] (ang.).
N.N. Harbeck N.N. i inni, Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy, „Annals of Oncology”, 22 (6), 2011, s. 1250–1258, DOI: 10.1093/annonc/mdq543, PMID: 21112929 [dostęp 2024-05-05] (ang.).
Sandra M.S.M. Swain Sandra M.S.M., Fredrick S.F.S. Whaley Fredrick S.F.S., Michael S.M.S. Ewer Michael S.M.S., Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials, „Cancer”, 97 (11), 2003, s. 2869–2879, DOI: 10.1002/cncr.11407, PMID: 12767102 [dostęp 2024-05-05] (ang.).
Michael R.M.R. Bristow Michael R.M.R. i inni, Early anthracycline cardiotoxicity, „The American Journal of Medicine”, 65 (5), 1978, s. 823–832, DOI: 10.1016/0002-9343(78)90802-1, PMID: 707541 [dostęp 2024-05-05] (ang.).
Seppo W.S.W. Langer Seppo W.S.W., Dexrazoxane for the treatment of chemotherapy-related side effects, „Cancer Management and Research”, 6, 2014, s. 357–363, DOI: 10.2147/CMAR.S47238, PMID: 25246808, PMCID: PMC4168851 [dostęp 2024-05-05] (ang.).
D.D. VonD.D.V. Hoff D.D. VonD.D.V. i inni, Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases, „The American Journal of Medicine”, 62 (2), 1977, s. 200–208, DOI: 10.1016/0002-9343(77)90315-1, PMID: 835599 [dostęp 2024-05-05] (ang.).
MariaM. Volkova MariaM., RaymondR. Russell RaymondR., Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment, „Current Cardiology Reviews”, 7 (4), 2011, s. 214–220, DOI: 10.2174/157340311799960645, PMID: 22758622, PMCID: PMC3322439 [dostęp 2024-05-05] (ang.).
L.C.L.C. Kremer L.C.L.C. i inni, Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study, „Journal of Clinical Oncology”, 19 (1), 2001, s. 191–196, DOI: 10.1200/JCO.2001.19.1.191, PMID: 11134212 [dostęp 2024-05-05] (ang.).
S.E.S.E. Lipshultz S.E.S.E. i inni, Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood, „The New England Journal of Medicine”, 324 (12), 1991, s. 808–815, DOI: 10.1056/NEJM199103213241205, PMID: 1997853 [dostęp 2024-05-05] (ang.).
Paulo J.P.J. Oliveira Paulo J.P.J. i inni, Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity, „Toxicology and Applied Pharmacology”, 200 (2), 2004, s. 159–168, DOI: 10.1016/j.taap.2004.04.005, PMID: 15476868 [dostęp 2024-05-05] (ang.).
PaoloP. Spallarossa PaoloP. i inni, Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro, „Journal of Molecular and Cellular Cardiology”, 37 (4), 2004, s. 837–846, DOI: 10.1016/j.yjmcc.2004.05.024, PMID: 15380674 [dostęp 2024-05-05] (ang.).
DanielaD. Cardinale DanielaD. i inni, Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition, „Circulation”, 114 (23), 2006, s. 2474–2481, DOI: 10.1161/CIRCULATIONAHA.106.635144, PMID: 17101852 [dostęp 2024-05-05] (ang.).
M.E.R.M.E.R. O'Brien M.E.R.M.E.R. i inni, Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer, „Annals of Oncology”, 15 (3), 2004, s. 440–449, DOI: 10.1093/annonc/mdh097, PMID: 14998846 [dostęp 2024-05-05] (ang.).
T.T. Safra T.T. i inni, Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2, „Annals of Oncology”, 11 (8), 2000, s. 1029–1033, DOI: 10.1023/a:1008365716693, PMID: 11038041 [dostęp 2024-05-05] .
AbdulfattahA. Saidi AbdulfattahA., RamiR. Alharethi RamiR., Management of chemotherapy induced cardiomyopathy, „Current Cardiology Reviews”, 7 (4), 2011, s. 245–249, DOI: 10.2174/157340311799960681, PMID: 22758625, PMCID: PMC3322442 [dostęp 2024-05-05] (ang.).
J.J. Shapira J.J. i inni, Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation, „Cancer”, 65 (4), 1990, s. 870–873, DOI: 10.1002/1097-0142(19900215)65:4<870::aid-cncr2820650407>3.0.co;2-d, PMID: 2297656 [dostęp 2024-05-05] (ang.).
E.S.E.S. Casper E.S.E.S. i inni, A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors, „Cancer”, 68 (6), 1991, s. 1221–1229, DOI: 10.1002/1097-0142(19910915)68:6<1221::aid-cncr2820680607>3.0.co;2-r, PMID: 1873773 [dostęp 2024-05-05] (ang.).
M.M. Zalupski M.M. i inni, Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study, „Journal of the National Cancer Institute”, 83 (13), 1991, s. 926–932, DOI: 10.1093/jnci/83.13.926, PMID: 2067035 [dostęp 2024-05-05] (ang.).
KashifK. Kalam KashifK., Thomas H.T.H. Marwick Thomas H.T.H., Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis, „European Journal of Cancer”, 49 (13), 2013, s. 2900–2909, DOI: 10.1016/j.ejca.2013.04.030, PMID: 23706982 [dostęp 2024-05-05] (ang.).
S.M.S.M. Swain S.M.S.M. i inni, Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer, „Journal of Clinical Oncology”, 15 (4), 1997, s. 1318–1332, DOI: 10.1200/JCO.1997.15.4.1318, PMID: 9193323 [dostęp 2024-05-05] (ang.).
Barry H.B.H. Trachtenberg Barry H.B.H. i inni, Anthracycline-associated cardiotoxicity in survivors of childhood cancer, „Pediatric Cardiology”, 32 (3), 2011, s. 342–353, DOI: 10.1007/s00246-010-9878-3, PMID: 21221562 [dostęp 2024-05-05] (ang.).
P.D.P.D. King P.D.P.D., M.C.M.C. Perry M.C.M.C., Hepatotoxicity of chemotherapy, „The Oncologist”, 6 (2), 2001, s. 162–176, DOI: 10.1634/theoncologist.6-2-162, PMID: 11306728 [dostęp 2024-05-05] (ang.).
Victor J.V.J. Navarro Victor J.V.J., John R.J.R. Senior John R.J.R., Drug-related hepatotoxicity, „The New England Journal of Medicine”, 354 (7), 2006, s. 731–739, DOI: 10.1056/NEJMra052270, PMID: 16481640 [dostęp 2024-05-05] (ang.).
Sarah E.S.E. James Sarah E.S.E. i inni, Anti-cancer drug induced neurotoxicity and identification of Rho pathway signaling modulators as potential neuroprotectants, „Neurotoxicology”, 29 (4), 2008, s. 605–612, DOI: 10.1016/j.neuro.2008.04.008, PMID: 18539332, PMCID: PMC2615238 [dostęp 2024-05-05] (ang.).
Dawn L.D.L. Hershman Dawn L.D.L. i inni, Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline, „Journal of Clinical Oncology”, 32 (18), 2014, s. 1941–1967, DOI: 10.1200/JCO.2013.54.0914, PMID: 24733808 [dostęp 2024-05-07] (ang.).
MartaM. Seretny MartaM. i inni, Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis, „Pain”, 155 (12), 2014, s. 2461–2470, DOI: 10.1016/j.pain.2014.09.020, PMID: 25261162 [dostęp 2024-05-07] (ang.).
J.S.J.S. Hong J.S.J.S., J.J. Tian J.J., L.H.L.H. Wu L.H.L.H., The influence of chemotherapy-induced neurotoxicity on psychological distress and sleep disturbance in cancer patients, „Current Oncology (Toronto, Ont.)”, 21 (4), 2014, s. 174–180, DOI: 10.3747/co.21.1984, PMID: 25089099, PMCID: PMC4117615 [dostęp 2024-05-07] (ang.).
Janet M.J.M. Schloss Janet M.J.M. i inni, Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): a systematic review, „Clinical Nutrition”, 32 (6), 2013, s. 888–893, DOI: 10.1016/j.clnu.2013.04.007, PMID: 23647723 [dostęp 2024-05-07] (ang.).
LizL. Savage LizL., Chemotherapy-induced pain puzzles scientists, „Journal of the National Cancer Institute”, 99 (14), 2007, s. 1070–1071, DOI: 10.1093/jnci/djm072, PMID: 17623791 [dostęp 2024-05-07] (ang.).
KrzysztofK. Brzeziński KrzysztofK., Polineuropatia wywołana chemioterapią. Część I. Patofizjologia / Chemotherapy-induced polyneuropathy. Part I. Pathophysiology, „Contemporary Oncology”, 16 (1), 2012, s. 72–78, DOI: 10.5114/wo.2012.27341, PMID: 23788859, PMCID: PMC3687382 [dostęp 2024-05-07] (pol. • ang.).
Anthony J.A.J. Windebank Anthony J.A.J., WolfgangW. Grisold WolfgangW., Chemotherapy-induced neuropathy, „Journal of the Peripheral Nervous System”, 13 (1), 2008, s. 27–46, DOI: 10.1111/j.1529-8027.2008.00156.x, PMID: 18346229 [dostęp 2024-05-07] (ang.).
J.E.J.E. Mollman J.E.J.E. i inni, Unusual presentation of cis-platinum neuropathy, „Neurology”, 38 (3), 1988, s. 488–490, DOI: 10.1212/wnl.38.3.488, PMID: 3347355 [dostęp 2024-05-07] (ang.).
S.M.S.M. Grunberg S.M.S.M. i inni, Progressive paresthesias after cessation of therapy with very high-dose cisplatin, „Cancer Chemotherapy and Pharmacology”, 25 (1), 1989, s. 62–64, DOI: 10.1007/BF00694340, PMID: 2556219 [dostęp 2024-05-07] (ang.).
James WJ.W. Albers James WJ.W. i inni, Interventions for preventing neuropathy caused by cisplatin and related compounds, „Cochrane Database of Systematic Reviews”, 2014 (3), 2014, DOI: 10.1002/14651858.CD005228.pub4, PMID: 24687190, PMCID: PMC10891440 [dostęp 2024-05-07] (ang.).
J.P.J.P. Durand J.P.J.P. i inni, Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial, „Annals of Oncology”, 23 (1), 2012, s. 200–205, DOI: 10.1093/annonc/mdr045, PMID: 21427067 [dostęp 2024-05-07] (ang.).
Ellen M. LavoieE.M.L. Smith Ellen M. LavoieE.M.L. i inni, Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial, „Journal of the American Medical Association”, 309 (13), 2013, s. 1359–1367, DOI: 10.1001/jama.2013.2813, PMID: 23549581, PMCID: PMC3912515 [dostęp 2024-05-07] (ang.).
Julie E.J.E. Hammack Julie E.J.E. i inni, Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy, „Pain”, 98 (1-2), 2002, s. 195–203, DOI: 10.1016/s0304-3959(02)00047-7, PMID: 12098632 [dostęp 2024-05-07] (ang.).
Anna-LiisaA.L. Kautio Anna-LiisaA.L. i inni, Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms, „Journal of Pain and Symptom Management”, 35 (1), 2008, s. 31–39, DOI: 10.1016/j.jpainsymman.2007.02.043, PMID: 17980550 [dostęp 2024-05-07] (ang.).
Ravi D.R.D. Rao Ravi D.R.D. i inni, Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3), „Cancer”, 110 (9), 2007, s. 2110–2118, DOI: 10.1002/cncr.23008, PMID: 17853395 [dostęp 2024-05-07] (ang.).
Debra L.D.L. Barton Debra L.D.L. i inni, A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA, „Supportive Care in Cancer”, 19 (6), 2011, s. 833–841, DOI: 10.1007/s00520-010-0911-0, PMID: 20496177, PMCID: PMC3338170 [dostęp 2024-05-07] (ang.).
F.F. Ries F.F., J.J. Klastersky J.J., Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity, „American Journal of Kidney Diseases”, 8 (5), 1986, s. 368–379, DOI: 10.1016/s0272-6386(86)80112-3, PMID: 3538860 [dostęp 2024-05-07] (ang.).
Benjamin D.B.D. Humphreys Benjamin D.B.D., Robert J.R.J. Soiffer Robert J.R.J., Colm C.C.C. Magee Colm C.C.C., Renal failure associated with cancer and its treatment: an update, „Journal of the American Society of Nephrology: JASN”, 16 (1), 2005, s. 151–161, DOI: 10.1681/ASN.2004100843, PMID: 15574506 [dostęp 2024-05-07] (ang.).
VaibhavV. Sahni VaibhavV., DevasmitaD. Choudhury DevasmitaD., ZiauddinZ. Ahmed ZiauddinZ., Chemotherapy-associated renal dysfunction, „Nature Reviews. Nephrology”, 5 (8), 2009, s. 450–462, DOI: 10.1038/nrneph.2009.97, PMID: 19564889 [dostęp 2024-05-07] (ang.).
J.J. Richmond J.J. i inni, Renal lesions associated with malignant lymphomas, „The American Journal of Medicine”, 32, 1962, s. 184–207, DOI: 10.1016/0002-9343(62)90289-9, PMID: 14492019 [dostęp 2024-05-17] (ang.).
TakashiT. Taguchi TakashiT. i inni, Cisplatin-associated nephrotoxicity and pathological events, „Contributions to Nephrology”, 148, 2005, s. 107–121, DOI: 10.1159/000086055, PMID: 15912030 [dostęp 2024-05-17] (ang.).
M.M. Lam M.M., D.J.D.J. Adelstein D.J.D.J., Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin, „American Journal of Kidney Diseases”, 8 (3), 1986, s. 164–169, DOI: 10.1016/s0272-6386(86)80020-8, PMID: 3752072 [dostęp 2024-05-17] (ang.).
H.H. Lajer H.H. i inni, Magnesium depletion enhances cisplatin-induced nephrotoxicity, „Cancer Chemotherapy and Pharmacology”, 56 (5), 2005, s. 535–542, DOI: 10.1007/s00280-005-1010-7, PMID: 15947931 [dostęp 2024-05-17] (ang.).
IstvanI. Arany IstvanI., Robert L.R.L. Safirstein Robert L.R.L., Cisplatin nephrotoxicity, „Seminars in Nephrology”, 23 (5), 2003, s. 460–464, DOI: 10.1016/s0270-9295(03)00089-5, PMID: 13680535 [dostęp 2024-05-17] (ang.).
VincentV. Launay-Vacher VincentV. i inni, Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care, „Cancer Chemotherapy and Pharmacology”, 61 (6), 2008, s. 903–909, DOI: 10.1007/s00280-008-0711-0, PMID: 18317762 [dostęp 2024-05-17] (ang.).
R.R. Skinner R.R. i inni, Ifosfamide, mesna, and nephrotoxicity in children, „Journal of Clinical Oncology”, 11 (1), 1993, s. 173–190, DOI: 10.1200/JCO.1993.11.1.173, PMID: 8418231 [dostęp 2024-05-17] (ang.).
C.B.C.B. Pratt C.B.C.B. i inni, Ifosfamide, Fanconi's syndrome, and rickets, „Journal of Clinical Oncology”, 9 (8), 1991, s. 1495–1499, DOI: 10.1200/JCO.1991.9.8.1495, PMID: 1649270 [dostęp 2024-05-17] (ang.).
R.R. Skinner R.R., Chronic ifosfamide nephrotoxicity in children, „Medical and Pediatric Oncology”, 41 (3), 2003, s. 190–197, DOI: 10.1002/mpo.10336, PMID: 12868118 [dostęp 2024-05-17] (ang.).
MustafaM. Cetiner MustafaM. i inni, Taurine protects against methotrexate-induced toxicity and inhibits leukocyte death, „Toxicology and Applied Pharmacology”, 209 (1), 2005, s. 39–50, DOI: 10.1016/j.taap.2005.03.009, PMID: 15890378 [dostęp 2024-05-17] (ang.).
Benjamin D.B.D. Humphreys Benjamin D.B.D. i inni, Gemcitabine-associated thrombotic microangiopathy, „Cancer”, 100 (12), 2004, s. 2664–2670, DOI: 10.1002/cncr.20290, PMID: 15197810 [dostęp 2024-05-17] (ang.).
Jay H.J.H. Ryu Jay H.J.H., Chemotherapy-induced pulmonary toxicity in lung cancer patients, „Journal of Thoracic Oncology”, 5 (9), 2010, s. 1313–1314, DOI: 10.1097/JTO.0b013e3181e9dbb9, PMID: 20736803 [dostęp 2024-05-17] (ang.).
NavtejN. Sathi NavtejN. i inni, How common is methotrexate pneumonitis? A large prospective study investigates, „Clinical Rheumatology”, 31 (1), 2012, s. 79–83, DOI: 10.1007/s10067-011-1758-6, PMID: 21638023 [dostęp 2024-05-17] (ang.).
MartinM. Schwaiblmair MartinM. i inni, Drug induced interstitial lung disease, „The Open Respiratory Medicine Journal”, 6, 2012, s. 63–74, DOI: 10.2174/1874306401206010063, PMID: 22896776, PMCID: PMC3415629 [dostęp 2024-05-17] (ang.).
BobbakB. Vahid BobbakB., Paul E.P.E. Marik Paul E.P.E., Pulmonary complications of novel antineoplastic agents for solid tumors, „Chest”, 133 (2), 2008, s. 528–538, DOI: 10.1378/chest.07-0851, PMID: 18252919 [dostęp 2024-05-17] (ang.).
Joseph R.J.R. Carver Joseph R.J.R. i inni, American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects, „Journal of Clinical Oncology”, 25 (25), 2007, s. 3991–4008, DOI: 10.1200/JCO.2007.10.9777, PMID: 17577017 [dostęp 2024-05-17] (ang.).
Andrew H.A.H. Limper Andrew H.A.H., Chemotherapy-induced lung disease, „Clinics in Chest Medicine”, 25 (1), 2004, s. 53–64, DOI: 10.1016/S0272-5231(03)00123-0, PMID: 15062597 [dostęp 2024-05-17] (ang.).
S.H.S.H. Abid S.H.S.H., V.V. Malhotra V.V., M.C.M.C. Perry M.C.M.C., Radiation-induced and chemotherapy-induced pulmonary injury, „Current Opinion in Oncology”, 13 (4), 2001, s. 242–248, DOI: 10.1097/00001622-200107000-00006, PMID: 11429481 [dostęp 2024-05-17] (ang.).
Alice DeA.D. Sanctis Alice DeA.D. i inni, Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer, „Cancer”, 117 (14), 2011, s. 3069–3080, DOI: 10.1002/cncr.25894, PMID: 21283982 [dostęp 2024-05-17] (ang.).
J.A. PérezJ.A.P. Fidalgo J.A. PérezJ.A.P. i inni, Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines, „Annals of Oncology”, 23 Suppl 7, 2012, vii167–173, DOI: 10.1093/annonc/mds294, PMID: 22997449 [dostęp 2024-05-17] (ang.).
D.L.D.L. Schrijvers D.L.D.L., Extravasation: a dreaded complication of chemotherapy, „Annals of Oncology”, 14 Suppl 3, 2003, iii26–30, DOI: 10.1093/annonc/mdg744, PMID: 12821535 [dostęp 2024-05-17] (ang.).
LisaL. Schulmeister LisaL., Managing vesicant extravasations, „The Oncologist”, 13 (3), 2008, s. 284–288, DOI: 10.1634/theoncologist.2007-0191, PMID: 18378538 [dostęp 2024-05-17] (ang.).
G.G. Bertelli G.G. i inni, Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study, „Journal of Clinical Oncology”, 13 (11), 1995, s. 2851–2855, DOI: 10.1200/JCO.1995.13.11.2851, PMID: 7595748 [dostęp 2024-05-17] (ang.).
J.J.J.J. Disa J.J.J.J. i inni, Prevention of adriamycin-induced full-thickness skin loss using hyaluronidase infiltration, „Plastic and Reconstructive Surgery”, 101 (2), 1998, s. 370–374, DOI: 10.1097/00006534-199802000-00016, PMID: 9462769 [dostęp 2024-05-17] (ang.).
H.T.H.T. Mouridsen H.T.H.T. i inni, Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies, „Annals of Oncology”, 18 (3), 2007, s. 546–550, DOI: 10.1093/annonc/mdl413, PMID: 17185744 [dostęp 2024-05-17] (ang.).
Ann M.A.M. Berger Ann M.A.M. i inni, NCCN Clinical Practice Guidelines Cancer-related fatigue, „Journal of the National Comprehensive Cancer Network”, 8 (8), 2010, s. 904–931, DOI: 10.6004/jnccn.2010.0067, PMID: 20870636 [dostęp 2024-05-17] (ang.).
RobertoR. Stasi RobertoR. i inni, Cancer-related fatigue: evolving concepts in evaluation and treatment, „Cancer”, 98 (9), 2003, s. 1786–1801, DOI: 10.1002/cncr.11742, PMID: 14584059 [dostęp 2024-05-17] (ang.).
MaartenM. Hofman MaartenM. i inni, Cancer-related fatigue: the scale of the problem, „The Oncologist”, 12 Suppl 1, 2007, s. 4–10, DOI: 10.1634/theoncologist.12-S1-4, PMID: 17573451 [dostęp 2024-05-17] (ang.).
Marianne J.M.J. Hjermstad Marianne J.M.J. i inni, Fatigue in long-term Hodgkin's Disease survivors: a follow-up study, „Journal of Clinical Oncology”, 23 (27), 2005, s. 6587–6595, DOI: 10.1200/JCO.2005.09.936, PMID: 16170166 [dostęp 2024-05-19] (ang.).
Marianne J.M.J. Hjermstad Marianne J.M.J. i inni, Fatigue in long-term Hodgkin's Disease survivors: a follow-up study, „Journal of Clinical Oncology”, 23 (27), 2005, s. 6587–6595, DOI: 10.1200/JCO.2005.09.936, PMID: 16170166 [dostęp 2024-05-17] (ang.).
JulieJ. Lemieux JulieJ., ElizabethE. Maunsell ElizabethE., LouiseL. Provencher LouiseL., Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review, „Psycho-Oncology”, 17 (4), 2008, s. 317–328, DOI: 10.1002/pon.1245, PMID: 17721909 [dostęp 2024-05-17] (ang.).
G.M.G.M. Kiebert G.M.G.M. i inni, Effect of peri-operative chemotherapy on the quality of life of patients with early breast cancer, „European Journal of Cancer”, 26 (10), 1990, s. 1038–1042, DOI: 10.1016/0277-5379(90)90046-v, PMID: 2148877 [dostęp 2024-05-17] (ang.).
N.N. Kluger N.N. i inni, Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients, „Annals of Oncology”, 23 (11), 2012, s. 2879–2884, DOI: 10.1093/annonc/mds095, PMID: 22571858 [dostęp 2024-05-17] (ang.).
E.G.E.G. Grevelman E.G.E.G., W.P.M.W.P.M. Breed W.P.M.W.P.M., Prevention of chemotherapy-induced hair loss by scalp cooling, „Annals of Oncology”, 16 (3), 2005, s. 352–358, DOI: 10.1093/annonc/mdi088, PMID: 15642703 [dostęp 2024-05-17] (ang.).
Manon M.C.M.M.C. Komen Manon M.C.M.M.C. i inni, Factors influencing the effectiveness of scalp cooling in the prevention of chemotherapy-induced alopecia, „The Oncologist”, 18 (7), 2013, s. 885–891, DOI: 10.1634/theoncologist.2012-0332, PMID: 23650021, PMCID: PMC3720643 [dostęp 2024-05-17] (ang.).
C.C. Macduff C.C. i inni, The effectiveness of scalp cooling in preventing alopecia for patients receiving epirubicin and docetaxel, „European Journal of Cancer Care”, 12 (2), 2003, s. 154–161, DOI: 10.1046/j.1365-2354.2003.00382.x, PMID: 12787013 [dostęp 2024-05-17] (ang.).
I.G.I.G. Ron I.G.I.G. i inni, Scalp cooling in the prevention of alopecia in patients receiving depilating chemotherapy, „Supportive Care in Cancer”, 5 (2), 1997, s. 136–138, DOI: 10.1007/BF01262571, PMID: 9069614 [dostęp 2024-05-17] (ang.).
B.B. Satterwhite B.B., S.S. Zimm S.S., The use of scalp hypothermia in the prevention of doxorubicin-induced hair loss, „Cancer”, 54 (1), 1984, s. 34–37, DOI: 10.1002/1097-0142(19840701)54:1<34::aid-cncr2820540109>3.0.co;2-w, PMID: 6372986 [dostęp 2024-05-17] (ang.).
P.P. Chirac P.P., R.R. Laing R.R., Updating the WHO essential drugs list, „The Lancet”, 357 (9262), 2001, s. 1134, DOI: 10.1016/S0140-6736(00)04291-4, PMID: 11303617 [dostęp 2024-05-17] (ang.).
MonaM. Ridderheim MonaM., MariaM. Bjurberg MariaM., AnitaA. Gustavsson AnitaA., Scalp hypothermia to prevent chemotherapy-induced alopecia is effective and safe: a pilot study of a new digitized scalp-cooling system used in 74 patients, „Supportive Care in Cancer”, 11 (6), 2003, s. 371–377, DOI: 10.1007/s00520-003-0451-y, PMID: 12768403 [dostęp 2024-05-17] (ang.).
M.M. Lemenager M.M. i inni, Effectiveness of cold cap in the prevention of docetaxel-induced alopecia, „European Journal of Cancer”, 33 (2), 1997, s. 297–300, DOI: 10.1016/s0959-8049(96)00374-7, PMID: 9135504 [dostęp 2024-05-17] (ang.).
M.M. Duvic M.M. i inni, A randomized trial of minoxidil in chemotherapy-induced alopecia, „Journal of the American Academy of Dermatology”, 35 (1), 1996, s. 74–78, DOI: 10.1016/S0190-9622(96)90500-9, PMID: 8682968 [dostęp 2024-05-19] (ang.).
M.M. Hidalgo M.M. i inni, A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia, „Anti-Cancer Drugs”, 10 (4), 1999, s. 393–395, DOI: 10.1097/00001813-199904000-00007, PMID: 10378674 [dostęp 2024-05-19] (ang.).
TeriT. Vega-Stromberg TeriT., Chemotherapy-induced secondary malignancies, „Journal of Infusion Nursing: The Official Publication of the Infusion Nurses Society”, 26 (6), 2003, s. 353–361, DOI: 10.1097/00129804-200311000-00004, PMID: 14624175 [dostęp 2024-05-19] (ang.).
L.B.L.B. Travis L.B.L.B. i inni, Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma, „Journal of the National Cancer Institute”, 87 (7), 1995, s. 524–530, DOI: 10.1093/jnci/87.7.524, PMID: 7707439 [dostęp 2024-05-19] (ang.).
AlissaA. Martin AlissaA. i inni, Secondary malignant neoplasms after high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma, „Pediatric Blood & Cancer”, 61 (8), 2014, s. 1350–1356, DOI: 10.1002/pbc.25033, PMID: 24634399 [dostęp 2024-05-19] (ang.).
S.S. Viviani S.S. i inni, Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD, „European Journal of Cancer & Clinical Oncology”, 21 (5), 1985, s. 601–605, DOI: 10.1016/0277-5379(85)90088-4, PMID: 2408897 [dostęp 2024-05-19] (ang.).
J.J. Wang J.J., K.A.K.A. Galil K.A.K.A., B.P.B.P. Setchell B.P.B.P., Changes in testicular blood flow and testosterone production during aspermatogenesis after irradiation, „The Journal of Endocrinology”, 98 (1), 1983, s. 35–46, DOI: 10.1677/joe.0.0980035, PMID: 6408218 [dostęp 2024-05-19] (ang.).
D.D. Meirow D.D., D.D. Nugent D.D., The effects of radiotherapy and chemotherapy on female reproduction, „Human Reproduction Update”, 7 (6), 2001, s. 535–543, DOI: 10.1093/humupd/7.6.535, PMID: 11727861 [dostęp 2024-05-19] (ang.).
Jonathan L.J.L. Tilly Jonathan L.J.L., Richard N.R.N. Kolesnick Richard N.R.N., Sphingolipids, apoptosis, cancer treatments and the ovary: investigating a crime against female fertility, „Biochimica Et Biophysica Acta”, 1585 (2-3), 2002, s. 135–138, DOI: 10.1016/s1388-1981(02)00333-5, PMID: 12531546 [dostęp 2024-05-19] (ang.).
R.L.R.L. Schilsky R.L.R.L. i inni, Long-term follow up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease, „The American Journal of Medicine”, 71 (4), 1981, s. 552–556, DOI: 10.1016/0002-9343(81)90205-9, PMID: 7282743 [dostęp 2024-05-19] (ang.).
J.J. Byrne J.J. i inni, Early menopause in long-term survivors of cancer during adolescence, „American Journal of Obstetrics and Gynecology”, 166 (3), 1992, s. 788–793, DOI: 10.1016/0002-9378(92)91335-8, PMID: 1550144 [dostęp 2024-05-19] (ang.).
S.J.S.J. Howell S.J.S.J. i inni, Bone mineral density in women with cytotoxic-induced ovarian failure, „Clinical Endocrinology”, 49 (3), 1998, s. 397–402, DOI: 10.1046/j.1365-2265.1998.00550.x, PMID: 9861333 [dostęp 2024-05-19] (ang.).
R.M.R.M. Chapman R.M.R.M., S.B.S.B. Sutcliffe S.B.S.B., Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's disease, „Blood”, 58 (4), 1981, s. 849–851, DOI: 10.1182/blood.V58.4.849.849, PMID: 7272513 [dostęp 2024-05-19] (ang.).
J.H.J.H. Waxman J.H.J.H. i inni, Failure to preserve fertility in patients with Hodgkin's disease, „Cancer Chemotherapy and Pharmacology”, 19 (2), 1987, s. 159–162, DOI: 10.1007/BF00254570, PMID: 31059063105906 [dostęp 2024-05-19] .
J.J. Blatt J.J. i inni, Pregnancy outcome following cancer chemotherapy, „The American Journal of Medicine”, 69 (6), 1980, s. 828–832, DOI: 10.1016/s0002-9343(80)80007-6, PMID: 7446548 [dostęp 2024-05-19] (ang.).
E.E.E.E. Reynoso E.E.E.E. i inni, Acute leukemia during pregnancy: the Toronto Leukemia Study Group experience with long-term follow-up of children exposed in utero to chemotherapeutic agents, „Journal of Clinical Oncology”, 5 (7), 1987, s. 1098–1106, DOI: 10.1200/JCO.1987.5.7.1098, PMID: 3474357 [dostęp 2024-05-19] (ang.).
JosefJ. Warkany JosefJ., Aminopterin and methotrexate: Folic acid deficiency, „Teratology”, 17 (3), 1978, s. 353–357, DOI: 10.1002/tera.1420170314, PMID: 675555 [dostęp 2024-05-19] (ang.).
R.D.R.D. Kozlowski R.D.R.D. i inni, Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease, „The American Journal of Medicine”, 88 (6), 1990, s. 589–592, DOI: 10.1016/0002-9343(90)90522-f, PMID: 2189302 [dostęp 2024-05-19] (ang.).
E.J.E.J. Lammer E.J.E.J. i inni, Retinoic acid embryopathy, „The New England Journal of Medicine”, 313 (14), 1985, s. 837–841, DOI: 10.1056/NEJM198510033131401, PMID: 3162101 [dostęp 2024-05-19] (ang.).
D.R.D.R. Soprano D.R.D.R., K.J.K.J. Soprano K.J.K.J., Retinoids as teratogens, „Annual Review of Nutrition”, 15, 1995, s. 111–132, DOI: 10.1146/annurev.nu.15.070195.000551, PMID: 8527214 [dostęp 2024-05-19] (ang.).
J.J.J.J. Turchi J.J.J.J., C.C. Villasis C.C., Anthracyclines in the treatment of malignancy in pregnancy, „Cancer”, 61 (3), 1988, s. 435–440, DOI: 10.1002/1097-0142(19880201)61:3<435::aid-cncr2820610305>3.0.co;2-f, PMID: 3276379 [dostęp 2024-05-19] (ang.).
F.P.F.P. Li F.P.F.P. i inni, Offspring of patients treated for cancer in childhood, „Journal of the National Cancer Institute”, 62 (5), 1979, s. 1193–1197, DOI: 10.1093/jnci/62.5.1193, PMID: 286096 [dostęp 2024-05-19] (ang.).
Sophie D.S.D. Fosså Sophie D.S.D. i inni, Parenthood in survivors after adulthood cancer and perinatal health in their offspring: a preliminary report, „Journal of the National Cancer Institute. Monographs” (34), 2005, s. 77–82, DOI: 10.1093/jncimonographs/lgi019, PMID: 15784830 [dostęp 2024-05-19] (ang.).
J.J.J.J. Mulvihill J.J.J.J. i inni, Pregnancy outcome in cancer patients. Experience in a large cooperative group, „Cancer”, 60 (5), 1987, s. 1143–1150, DOI: 10.1002/1097-0142(19870901)60:5<1143::aid-cncr2820600537>3.0.co;2-e, PMID: 3607730 [dostęp 2024-05-19] (ang.).
J.J. Aisner J.J., P.H.P.H. Wiernik P.H.P.H., P.P. Pearl P.P., Pregnancy outcome in patients treated for Hodgkin's disease, „Journal of Clinical Oncology”, 11 (3), 1993, s. 507–512, DOI: 10.1200/JCO.1993.11.3.507, PMID: 8445425 [dostęp 2024-05-19] (ang.).
Jeffrey S.J.S. Wefel Jeffrey S.J.S. i inni, The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial, „Cancer”, 100 (11), 2004, s. 2292–2299, DOI: 10.1002/cncr.20272, PMID: 15160331 [dostęp 2024-05-19] (ang.).
Thomas H.T.H. Connor Thomas H.T.H., Melissa A.M.A. McDiarmid Melissa A.M.A., Preventing occupational exposures to antineoplastic drugs in health care settings, „CA: A Cancer Journal for Clinicians”, 56 (6), 2006, s. 354–365, DOI: 10.3322/canjclin.56.6.354, PMID: 17135692 [dostęp 2024-05-19] (ang.).
GeorgeG. Dranitsaris GeorgeG. i inni, Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta-analysis of the literature, „Journal of Oncology Pharmacy Practice: Official Publication of the International Society of Oncology Pharmacy Practitioners”, 11 (2), 2005, s. 69–78, DOI: 10.1191/1078155205jp155oa, PMID: 16465719 [dostęp 2024-05-19] (ang.).
T.T. Skov T.T. i inni, Leukaemia and reproductive outcome among nurses handling antineoplastic drugs, „British Journal of Industrial Medicine”, 49 (12), 1992, s. 855–861, DOI: 10.1136/oem.49.12.855, PMID: 1472444, PMCID: PMC1061216 [dostęp 2024-05-19] (ang.).
T.T. Skov T.T. i inni, Risks for physicians handling antineoplastic drugs, „The Lancet”, 336 (8728), 1990, s. 1446, DOI: 10.1016/0140-6736(90)93148-i, PMID: 1978899 [dostęp 2024-05-19] (ang.).

iiarjournals.org

iv.iiarjournals.org

EmelineE. Pape EmelineE. i inni, Leptomeningeal metastasis in melanoma: a prospective clinical study of nine patients, „In Vivo”, 26 (6), 2012, s. 1079–1086, PMID: 23160697 [dostęp 2024-04-30] (ang.).

kup.at

WolfgangW. Grisold WolfgangW., StefanS. Oberndorfer StefanS., Anthony J.A.J. Windebank Anthony J.A.J., Chemotherapy and Polyneuropathies, „European Association of NeuroOncology”, 1, 2, 2012, s. 25–36 [dostęp 2024-05-07] (ang.).

mp.pl

indeks.mp.pl

Merkaptopuryna, [w:] Indeks Leków MP, lista preparatów, Medycyna Praktyczna [dostęp 2024-04-22] .
Bleomycyna, [w:] Indeks Leków MP, lista preparatów, Medycyna Praktyczna [dostęp 2024-04-22] .
Mp.pl, Kapecytabina karta leku [dostęp 2015-02-06] .
Pregabalina. Karta leku.

nih.gov

ncbi.nlm.nih.gov

Vincent T.V.T. DeVita Vincent T.V.T., EdwardE. Chu EdwardE., A History of Cancer Chemotherapy, „Cancer Research”, 68 (21), 2008, s. 8643–8653, DOI: 10.1158/0008-5472.CAN-07-6611, PMID: 18974103 [dostęp 2024-04-22] (ang.).
KjK. Williams KjK., The introduction of ‘chemotherapy’ using arsphenamine – the first magic bullet, „Journal of the Royal Society of Medicine”, 102 (8), 2009, s. 343–348, DOI: 10.1258/jrsm.2009.09k036, PMID: 19679737, PMCID: PMC2726818 [dostęp 2024-04-22] (ang.).
A.A. Gilman A.A., Therapeutic applications of chemical warfare agents, „Federation Proceedings”, 5, 1946, s. 285–292, PMID: 20990888 [dostęp 2024-04-22] .
Louis S.L.S. Goodman Louis S.L.S., Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin’s disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders, „Journal of the American Medical Association”, 132 (3), 1946, s. 126, DOI: 10.1001/jama.1946.02870380008004, PMID: 20997191 [dostęp 2024-04-22] (ang.).
SidneyS. Farber SidneyS. i inni, Temporary Remissions in Acute Leukemia in Children Produced by Folic Acid Antagonist, 4-Aminopteroyl-Glutamic Acid (Aminopterin), „The New England Journal of Medicine”, 238 (23), 1948, s. 787–793, DOI: 10.1056/NEJM194806032382301, PMID: 18860765 [dostęp 2024-04-22] (ang.).
Denis R.D.R. Miller Denis R.D.R., A tribute to Sidney Farber – the father of modern chemotherapy, „British Journal of Haematology”, 134 (1), 2006, s. 20–26, DOI: 10.1111/j.1365-2141.2006.06119.x, PMID: 16803563 [dostęp 2024-04-22] (ang.).
J.C.J.C. Wright J.C.J.C. i inni, An evaluation of folic acid antagonists in adults with neoplastic diseases: a study of 93 patients with incurable neoplasms, „Journal of the National Medical Association”, 43 (4), 1951, s. 211–240, PMID: 14850976, PMCID: PMC2616951 [dostęp 2024-04-22] (ang.).
CharlesCh. Heidelberger CharlesCh. i inni, Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory Compounds, „Nature”, 179 (4561), 1957, s. 663–666, DOI: 10.1038/179663a0, PMID: 13418758 [dostęp 2024-04-22] (ang.).
George H.G.H. Hitchings George H.G.H., Gertrude B.G.B. Elion Gertrude B.G.B., The chemistry and biochemistry of purine analogs, „Annals of the New York Academy of Sciences”, 60 (2), 1954, s. 195–199, DOI: 10.1111/j.1749-6632.1954.tb40008.x, PMID: 14350523 [dostęp 2024-04-22] (ang.).
R.R. Hertz R.R., M.C.M.C. Li M.C.M.C., D.B.D.B. Spencer D.B.D.B., Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma, „Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine”, 93 (2), 1956, s. 361–366, DOI: 10.3181/00379727-93-22757, PMID: 13379512 [dostęp 2024-04-22] (ang.).
E.E. Frei E.E. i inni, The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia, „Blood”, 26 (5), 1965, s. 642–656, DOI: 10.1182/blood.V26.5.642.642, PMID: 5321112 [dostęp 2024-04-22] (ang.).
BarnettB. Rosenberg BarnettB., Loretta VanL.V. Camp Loretta VanL.V., ThomasT. Krigas ThomasT., Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode, „Nature”, 205 (4972), 1965, s. 698–699, DOI: 10.1038/205698a0, PMID: 14287410 [dostęp 2024-04-22] (ang.).
G.G. Damia G.G., M.M. D'Incalci M.M., Mechanisms of resistance to alkylating agents, „Cytotechnology”, 27 (1/3), 1998, s. 165–173, DOI: 10.1023/A:1008060720608, PMID: 19002790, PMCID: PMC3449574 [dostęp 2024-04-22] (ang.).
Christopher W.Ch.W. Carreras Christopher W.Ch.W., Daniel V.D.V. Santi Daniel V.D.V., The catalytic mechanism and structure of thymidylate synthase, „Annual Review of Biochemistry”, 64 (1), 1995, s. 721–762, DOI: 10.1146/annurev.bi.64.070195.003445, PMID: 7574499 [dostęp 2024-04-22] (ang.).
ValérieV. Ganansia-Leymarie ValérieV. i inni, Signal transduction pathways of taxanes-induced apoptosis, „Current Medicinal Chemistry. Anti-Cancer Agents”, 3 (4), 2003, s. 291–306, DOI: 10.2174/1568011033482422, PMID: 12769774 [dostęp 2024-04-22] (ang.).
YiY. Huang YiY. i inni, Regulation of Vinca alkaloid-induced apoptosis by NF-kappaB/IkappaB pathway in human tumor cells, „Molecular Cancer Therapeutics”, 3 (3), 2004, s. 271–277, DOI: 10.1158/1535-7163.271.3.3, PMID: 15026547 [dostęp 2024-04-22] (ang.).
MarcinM. Koba MarcinM., JerzyJ. Konopa JerzyJ., Aktynomycyna D i mechanizmy jej działania, „Postępy Higieny i Medycyny Doświadczalnej”, 59, 2005, s. 290–298, PMID: 15995596 [zarchiwizowane 2017-06-20] .
R.T.R.T. Dorr R.T.R.T., Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics, „Seminars in Oncology”, 19 (2 Suppl 5), 1992, s. 3–8, PMID: 1384141 [dostęp 2024-04-22] (ang.).
Manuel M.M.M. Paz Manuel M.M.M. i inni, A New Mechanism of Action for the Anticancer Drug Mitomycin C: Mechanism-Based Inhibition of Thioredoxin Reductase, „Chemical Research in Toxicology”, 25 (7), 2012, s. 1502–1511, DOI: 10.1021/tx3002065, PMID: 22694104 [dostęp 2024-04-22] (ang.).
M.M. Tomasz M.M., Mitomycin C: small, fast and deadly (but very selective), „Chemistry & Biology”, 2 (9), 1995, s. 575–579, DOI: 10.1016/1074-5521(95)90120-5, PMID: 9383461 [dostęp 2024-04-22] (ang.).
G.G. Makin G.G., J.A.J.A. Hickman J.A.J.A., Apoptosis and cancer chemotherapy, „Cell and Tissue Research”, 301 (1), 2000, s. 143–152, DOI: 10.1007/s004419900160, PMID: 10928287 [dostęp 2024-04-22] (ang.).
Richard J.R.J. Epstein Richard J.R.J., Maintenance Therapy to Suppress Micrometastasis: The New Challenge for Adjuvant Cancer Treatment, „Clinical Cancer Research”, 11 (15), 2005, s. 5337–5341, DOI: 10.1158/1078-0432.CCR-05-0437, PMID: 16061845 [dostęp 2024-04-22] (ang.).
D.A.D.A. Eichenauer D.A.D.A. i inni, Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, „Annals of Oncology”, 25, 2014, iii70–iii75, DOI: 10.1093/annonc/mdu181, PMID: 25185243 [dostęp 2024-04-22] (ang.).
RamyaR. Thota RamyaR., James M.J.M. Pauff James M.J.M., Jordan D.J.D. Berlin Jordan D.J.D., Treatment of metastatic pancreatic adenocarcinoma: a review, „Oncology”, 28 (1), 2014, s. 70–74, PMID: 24683721 [dostęp 2024-04-22] (ang.).
A.A. Okines A.A. i inni, Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, „Annals of Oncology”, 21, 2010, v50–v54, DOI: 10.1093/annonc/mdq164, PMID: 20555102 [dostęp 2024-04-22] (ang.).
E. VanE.V. Cutsem E. VanE.V. i inni, Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, „Annals of Oncology”, 25, 2014, iii1–iii9, DOI: 10.1093/annonc/mdu260, PMID: 25190710 [dostęp 2024-04-22] (ang.).
M.M. Früh M.M. i inni, Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, „Annals of Oncology”, 24, 2013, vi99–vi105, DOI: 10.1093/annonc/mdt178, PMID: 23813929 [dostęp 2024-04-22] (ang.).
M.M. Reck M.M. i inni, Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, „Annals of Oncology”, 25, 2014, iii27–iii39, DOI: 10.1093/annonc/mdu199, PMID: 25115305 [dostęp 2024-04-22] (ang.).
V.V. Grégoire V.V. i inni, Squamous cell carcinoma of the head and neck: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up, „Annals of Oncology”, 21, 2010, v184–v186, DOI: 10.1093/annonc/mdq185, PMID: 20555077 [dostęp 2024-04-22] (ang.).
N.N. Kiyota N.N. i inni, Systemic Chemotherapy with Cisplatin Plus 5-FU (PF) for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN): Efficacy and Safety of a Lower Dose of PF (80/800) at a Single Institution in Japan, „Japanese Journal of Clinical Oncology”, 39 (4), 2009, s. 225–230, DOI: 10.1093/jjco/hyp002, PMID: 19211574 [dostęp 2024-04-22] (ang.).
E.E. Senkus E.E. i inni, Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, „Annals of Oncology”, 24, 2013, vi7–vi23, DOI: 10.1093/annonc/mdt284, PMID: 23970019 [dostęp 2024-04-22] (ang.).
William J.W.J. Gradishar William J.W.J. i inni, Breast cancer version 3.2014, „Journal of the National Comprehensive Cancer Network”, 12 (4), 2014, s. 542–590, DOI: 10.6004/jnccn.2014.0058, PMID: 24717572 [dostęp 2024-04-22] (ang.).
J.A.J.A. Ledermann J.A.J.A. i inni, Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, „Annals of Oncology”, 24, 2013, vi24–vi32, DOI: 10.1093/annonc/mdt333, PMID: 24078660 [dostęp 2024-04-22] (ang.).
Gary H.G.H. Lyman Gary H.G.H., Impact of chemotherapy dose intensity on cancer patient outcomes, „Journal of the National Comprehensive Cancer Network”, 7 (1), 2009, s. 99–108, DOI: 10.6004/jnccn.2009.0009, PMID: 19176210 [dostęp 2024-04-22] (ang.).
Marc L.M.L. Citron Marc L.M.L., Dose-Dense Chemotherapy: Principles, Clinical Results and Future Perspectives, „Breast Care”, 3 (4), 2008, s. 251–255, DOI: 10.1159/000148914, PMID: 21076605, PMCID: PMC2974980 [dostęp 2024-04-22] (ang.).
D.J.D.J. Dodwell D.J.D.J., H.H. Gurney H.H., N.N. Thatcher N.N., Dose intensity in cancer chemotherapy, „British Journal of Cancer”, 61 (6), 1990, s. 789–794, DOI: 10.1038/bjc.1990.178, PMID: 2164831, PMCID: PMC1971684 [dostęp 2024-04-22] (ang.).
ErickE. Gamelin ErickE. i inni, Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal Cancer, „Journal of Clinical Oncology”, 26 (13), 2008, s. 2099–2105, DOI: 10.1200/JCO.2007.13.3934, PMID: 18445839 [dostęp 2024-04-22] (ang.).
OlivierO. Capitain OlivierO. i inni, Individual Fluorouracil Dose Adjustment in FOLFOX Based on Pharmacokinetic Follow-Up Compared With Conventional Body-Area-Surface Dosing: A Phase II, Proof-of-Concept Study, „Clinical Colorectal Cancer”, 11 (4), 2012, s. 263–267, DOI: 10.1016/j.clcc.2012.05.004, PMID: 22683364 [dostęp 2024-04-22] (ang.).
D. DuD.D. Bois D. DuD.D., E.F. DuE.F.D. Bois E.F. DuE.F.D., A formula to estimate the approximate surface area if height and weight be known. 1916, „Nutrition”, 5 (5), 1989, s. 303–311, PMID: 2520314 [dostęp 2024-04-22] (ang.).
S.A.S.A. Kaestner S.A.S.A., G.J.G.J. Sewell G.J.G.J., Chemotherapy Dosing Part I: Scientific Basis for Current Practice and Use of Body Surface Area, „Clinical Oncology”, 19 (1), 2007, s. 23–37, DOI: 10.1016/j.clon.2006.10.010, PMID: 17305252 [dostęp 2024-04-22] (ang.).
D.D. Pinkel D.D., The use of body surface area as a criterion of drug dosage in cancer chemotherapy, „Cancer Research”, 18 (7), 1958, s. 853–856, PMID: 13573353 [dostęp 2024-04-22] (ang.).
Jan H.J.H. Beumer Jan H.J.H., EdwardE. Chu EdwardE., Salvatore J.S.J. Salamone Salvatore J.S.J., Body-Surface Area–Based Chemotherapy Dosing: Appropriate in the 21st Century?, „Journal of Clinical Oncology”, 30 (31), 2012, s. 3896–3897, DOI: 10.1200/JCO.2012.44.2863, PMID: 22965963 [dostęp 2024-04-22] (ang.).
Sharyn D.S.D. Baker Sharyn D.S.D. i inni, Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001, „Journal of the National Cancer Institute”, 94 (24), 2002, s. 1883–1888, DOI: 10.1093/jnci/94.24.1883, PMID: 12488482 [dostęp 2024-04-22] (ang.).
A.A. Felici A.A., J.J. Verweij J.J., A.A. Sparreboom A.A., Dosing strategies for anticancer drugs: the good, the bad and body-surface area, „European Journal of Cancer”, 38 (13), 2002, s. 1677–1684, DOI: 10.1016/s0959-8049(02)00151-x, PMID: 12175683 [dostęp 2024-04-22] (ang.).
M.AM.A. Rudek M.AM.A. i inni, Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy, „European Journal of Cancer”, 40 (8), 2004, s. 1170–1178, DOI: 10.1016/j.ejca.2003.12.026, PMID: 15110880 [dostęp 2024-04-22] (ang.).
HH. Gurney HH., How to calculate the dose of chemotherapy, „British Journal of Cancer”, 86 (8), 2002, s. 1297–1302, DOI: 10.1038/sj.bjc.6600139, PMID: 11953888, PMCID: PMC2375356 [dostęp 2024-04-22] (ang.).
Rodney J.R.J. Hunter Rodney J.R.J. i inni, Dosing chemotherapy in obese patients: Actual versus assigned body surface area (BSA), „Cancer Treatment Reviews”, 35 (1), 2009, s. 69–78, DOI: 10.1016/j.ctrv.2008.07.005, PMID: 18922643 [dostęp 2024-04-22] (ang.).
Jennifer J.J.J. Griggs Jennifer J.J.J. i inni, Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline, „Journal of Clinical Oncology”, 30 (13), 2012, s. 1553–1561, DOI: 10.1200/JCO.2011.39.9436, PMID: 22473167 [dostęp 2024-04-22] (ang.).
Rajesh R.R.R. Kaldate Rajesh R.R.R. i inni, Modeling the 5-Fluorouracil Area Under the Curve Versus Dose Relationship to Develop a Pharmacokinetic Dosing Algorithm for Colorectal Cancer Patients Receiving FOLFOX6, „The Oncologist”, 17 (3), 2012, s. 296–302, DOI: 10.1634/theoncologist.2011-0357, PMID: 22382460, PMCID: PMC3316912 [dostęp 2024-04-22] (ang.).
M. WasifM.W. Saif M. WasifM.W. i inni, Pharmacokinetically Guided Dose Adjustment of 5-Fluorouracil: A Rational Approach to Improving Therapeutic Outcomes, „Journal of the National Cancer Institute”, 101 (22), 2009, s. 1543–1552, DOI: 10.1093/jnci/djp328, PMID: 19841331 [dostęp 2024-04-22] (ang.).
Y.Y.Y.Y. Hon Y.Y.Y.Y., W.E.W.E. Evans W.E.W.E., Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach, „Clinical Chemistry”, 44 (2), 1998, s. 388–400, DOI: 10.1093/clinchem/44.2.388, PMID: 9474050 [dostęp 2024-04-22] (ang.).
Milly E deM.E. Jonge Milly E deM.E. i inni, Individualised Cancer Chemotherapy: Strategies and Performance of Prospective Studies on Therapeutic Drug Monitoring with Dose Adaptation: A Review, „Clinical Pharmacokinetics”, 44 (2), 2005, s. 147–173, DOI: 10.2165/00003088-200544020-00002, PMID: 15656695 [dostęp 2024-04-22] (ang.).
J.A.J.A. Ridge J.A.J.A., E.R.E.R. Sigurdson E.R.E.R., J.M.J.M. Daly J.M.J.M., Distribution of fluorodeoxyuridine uptake in the liver and colorectal hepatic metastases of human beings after arterial infusion, „Surgery, Gynecology & Obstetrics”, 164 (4), 1987, s. 319–323, PMID: 2951882 .
E.R.E.R. Sigurdson E.R.E.R. i inni, Tumor and liver drug uptake following hepatic artery and portal vein infusion, „Journal of Clinical Oncology”, 5 (11), 1987, s. 1836–1840, DOI: 10.1200/JCO.1987.5.11.1836, PMID: 3681370 [dostęp 2024-04-24] (ang.).
D.C.D.C. Hohn D.C.D.C. i inni, A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial., „Journal of Clinical Oncology”, 7 (11), 1989, s. 1646–1654, DOI: 10.1200/JCO.1989.7.11.1646, PMID: 2530317 [dostęp 2024-04-24] (ang.).
NancyN. Kemeny NancyN., Intrahepatic or Systemic Infusion of Fluorodeoxyuridine in Patients with Liver Metastases from Colorectal Carcinoma: A Randomized Trial, „Annals of Internal Medicine”, 107 (4), 1987, s. 459, DOI: 10.7326/0003-4819-107-4-459, PMID: 2957943 [dostęp 2024-04-24] (ang.).
Alfred E.A.E. Chang Alfred E.A.E. i inni, A Prospective Randomized Trial of Regional Versus Systemic Continuous 5-Fluorodeoxyuridine Chemotherapy in the Treatment of Colorectal Liver Metastases:, „Annals of Surgery”, 206 (6), 1987, s. 685–693, DOI: 10.1097/00000658-198712000-00001, PMID: 2961314, PMCID: PMC1493315 [dostęp 2024-04-24] (ang.).
NancyN. Kemeny NancyN. i inni, Phase I Trial of Systemic Oxaliplatin Combination Chemotherapy With Hepatic Arterial Infusion in Patients With Unresectable Liver Metastases From Colorectal Cancer, „Journal of Clinical Oncology”, 23 (22), 2005, s. 4888–4896, DOI: 10.1200/JCO.2005.07.100, PMID: 16009951 [dostęp 2024-04-24] (ang.).
NancyN. Kemeny NancyN. i inni, Hepatic Arterial Infusion of Chemotherapy after Resection of Hepatic Metastases from Colorectal Cancer, „The New England Journal of Medicine”, 341 (27), 1999, s. 2039–2048, DOI: 10.1056/NEJM199912303412702, PMID: 10615075 [dostęp 2024-04-24] (ang.).
M. MargaretM.M. Kemeny M. MargaretM.M. i inni, Combined-Modality Treatment for Resectable Metastatic Colorectal Carcinoma to the Liver: Surgical Resection of Hepatic Metastases in Combination With Continuous Infusion of Chemotherapy—An Intergroup Study, „Journal of Clinical Oncology”, 20 (6), 2002, s. 1499–1505, DOI: 10.1200/JCO.2002.20.6.1499, PMID: 11896097 [dostęp 2024-04-24] (ang.).
SergioS. Frustaci SergioS. i inni, Intra-arterial continuous infusion of cis-diamminedichloroplatinum in untreated head and neck cancer patients, „Cancer”, 57 (6), 1986, s. 1118–1123, DOI: 10.1002/1097-0142(19860315)57:6<1118::AID-CNCR2820570610>3.0.CO;2-5, PMID: 3943035 [dostęp 2024-04-24] (ang.).
J EJ.E. Mortimer J EJ.E. i inni, Feasibility and efficacy of weekly intraarterial cisplatin in locally advanced (stage III and IV) head and neck cancers., „Journal of Clinical Oncology”, 6 (6), 1988, s. 969–975, DOI: 10.1200/JCO.1988.6.6.969, PMID: 3373266 [dostęp 2024-04-24] (ang.).
LarsL. Podleska LarsL. i inni, Drug dosage in isolated limb perfusion: evaluation of a limb volume model for extremity volume calculation, „World Journal of Surgical Oncology”, 12 (1), 2014, s. 81, DOI: 10.1186/1477-7819-12-81, PMID: 24684972, PMCID: PMC3994217 [dostęp 2024-04-24] (ang.).
Tim D.T.D. Pencavel Tim D.T.D. i inni, Isolated limb perfusion with melphalan, tumour necrosis factor‐alpha and oncolytic vaccinia virus improves tumour targeting and prolongs survival in a rat model of advanced extremity sarcoma, „International Journal of Cancer”, 136 (4), 2015, s. 965–976, DOI: 10.1002/ijc.29059, PMID: 24978211 [dostęp 2024-04-24] (ang.).
DavidD. Moreno-Ramirez DavidD. i inni, Isolated Limb Perfusion for Malignant Melanoma: Systematic Review on Effectiveness and Safety, „The Oncologist”, 15 (4), 2010, s. 416–427, DOI: 10.1634/theoncologist.2009-0325, PMID: 20348274, PMCID: PMC3227960 [dostęp 2024-04-24] (ang.).
J.M.H.J.M.H. Hendriks J.M.H.J.M.H., P.E.Y. VanP.E.Y.V. Schil P.E.Y. VanP.E.Y.V., Isolated lung perfusion for the treatment of pulmonary metastases, „Surgical Oncology”, 7 (1-2), 1998, s. 59–63, DOI: 10.1016/S0960-7404(98)00028-0, PMID: 10421507 [dostęp 2024-04-24] (ang.).
Willem A. denW.A. Hengst Willem A. denW.A. i inni, Phase II Multicenter Clinical Trial of Pulmonary Metastasectomy and Isolated Lung Perfusion with Melphalan in Patients with Resectable Lung Metastases, „Journal of Thoracic Oncology”, 9 (10), 2014, s. 1547–1553, DOI: 10.1097/JTO.0000000000000279, PMID: 25105436 [dostęp 2024-04-24] (ang.).
Pierre-BenoitP.B. Pagès Pierre-BenoitP.B. i inni, Isolated Lung Perfusion as an Adjuvant Treatment of Colorectal Cancer Lung Metastases: A Preclinical Study in a Pig Model, „PLoS ONE”, 8 (3), 2013, e59485, DOI: 10.1371/journal.pone.0059485, PMID: 23527205, PMCID: PMC3601104 [dostęp 2024-04-24] (ang.).
W.A. DenW.A.D. Hengst W.A. DenW.A.D. i inni, Selective pulmonary artery perfusion with melphalan is equal to isolated lung perfusion but superior to intravenous melphalan for the treatment of sarcoma lung metastases in a rodent model, „European Journal of Cardio-Thoracic Surgery”, 42 (2), 2012, s. 341–347, DOI: 10.1093/ejcts/ezs017, PMID: 22345285 [dostęp 2024-04-24] (ang.).
MM. Markman MM. i inni, Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin., „Journal of Clinical Oncology”, 9 (10), 1991, s. 1801–1805, DOI: 10.1200/JCO.1991.9.10.1801, PMID: 1919630 [dostęp 2024-04-24] (ang.).
FredF. Shapiro FredF. i inni, High-Intensity Intravenous Cyclophosphamide and Cisplatin, Interim Surgical Debulking, and Intraperitoneal Cisplatin in Advanced Ovarian Carcinoma: A Pilot Trial with Ten-Year Follow-up, „Gynecologic Oncology”, 67 (1), 1997, s. 39–45, DOI: 10.1006/gyno.1997.4821, PMID: 9345354 [dostęp 2024-04-24] (ang.).
Helen J.H.J. Mackay Helen J.H.J. i inni, Phase II/III Study of Intraperitoneal Chemotherapy after Neoadjuvant Chemotherapy for Ovarian Cancer: NCIC CTG OV.21, „Current Oncology”, 18 (2), 2011, s. 84–90, DOI: 10.3747/co.v18i2.725, PMID: 21505599, PMCID: PMC3070707 [dostęp 2024-04-24] (ang.).
DD. Kelsen DD. i inni, Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil., „Journal of Clinical Oncology”, 14 (6), 1996, s. 1818–1828, DOI: 10.1200/JCO.1996.14.6.1818, PMID: 8656250 [dostęp 2024-04-24] (ang.).
O TO.T. Atiq O TO.T. i inni, Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer., „Journal of Clinical Oncology”, 11 (3), 1993, s. 425–433, DOI: 10.1200/JCO.1993.11.3.425, PMID: 8445416 [dostęp 2024-04-24] (ang.).
Andrew L.A.L. Feldman Andrew L.A.L. i inni, Analysis of Factors Associated With Outcome in Patients With Malignant Peritoneal Mesothelioma Undergoing Surgical Debulking and Intraperitoneal Chemotherapy, „Journal of Clinical Oncology”, 21 (24), 2003, s. 4560–4567, DOI: 10.1200/JCO.2003.04.150, PMID: 14673042 [dostęp 2024-04-24] (ang.).
MaurieM. Markman MaurieM., DavidD. Kelsen DavidD., Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma, „Journal of Cancer Research and Clinical Oncology”, 118 (7), 1992, s. 547–550, DOI: 10.1007/BF01225271, PMID: 1624547 [dostęp 2024-04-24] (ang.).
PeterP. Dyck PeterP., Lumbar reservoir for intrathecal chemotherapy, „Cancer”, 55 (12), 1985, s. 2771–2773, DOI: 10.1002/1097-0142(19850615)55:12<2771::AID-CNCR2820551208>3.0.CO;2-I, PMID: 3838918 [dostęp 2024-04-24] (ang.).
Eugenie A.M.T.E.A.M.T. Obbens Eugenie A.M.T.E.A.M.T. i inni, Ommaya reservoirs in 387 cancer patients: A 15‐year experience, „Neurology”, 35 (9), 1985, s. 1274–1274, DOI: 10.1212/WNL.35.9.1274, PMID: 3839573 [dostęp 2024-04-24] (ang.).
Yok-LamY.L. Kwong Yok-LamY.L., Dominic Y.M.D.Y.M. Yeung Dominic Y.M.D.Y.M., Joyce C.W.J.C.W. Chan Joyce C.W.J.C.W., Intrathecal chemotherapy for hematologic malignancies: drugs and toxicities, „Annals of Hematology”, 88 (3), 2009, s. 193–201, DOI: 10.1007/s00277-008-0645-y, PMID: 19050889 [dostęp 2024-04-24] (ang.).
N.N. Gokbuget N.N. i inni, Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma, „Haematologica”, 96 (2), 2011, s. 238–244, DOI: 10.3324/haematol.2010.028092, PMID: 20952517, PMCID: PMC3031691 [dostęp 2024-04-24] (ang.).
D.D. Martinez-Cuadron D.D. i inni, Central nervous system involvement at first relapse in patients with acute myeloid leukemia, „Haematologica”, 96 (9), 2011, s. 1375–1379, DOI: 10.3324/haematol.2011.042960, PMID: 21565904, PMCID: PMC3166110 [dostęp 2024-04-30] (ang.).
Koen vanK. Besien Koen vanK. i inni, Risk Factors, Treatment, and Outcome of Central Nervous System Recurrence in Adults With Intermediate-Grade and Immunoblastic Lymphoma, „Blood”, 91 (4), 1998, s. 1178–1184, DOI: 10.1182/blood.V91.4.1178, PMID: 9454747 [dostęp 2024-04-30] (ang.).
Ching-HonCh.H. Pui Ching-HonCh.H., EckhardE. Thiel EckhardE., Central Nervous System Disease in Hematologic Malignancies: Historical Perspective and Practical Applications, „Seminars in Oncology”, 36, 2009, S2–S16, DOI: 10.1053/j.seminoncol.2009.05.002, PMID: 19660680, PMCID: PMC2805279 [dostęp 2024-04-30] (ang.).
Lisa M.L.M. DeAngelis Lisa M.L.M. i inni, Combination Chemotherapy and Radiotherapy for Primary Central Nervous System Lymphoma: Radiation Therapy Oncology Group Study 93-10, „Journal of Clinical Oncology”, 20 (24), 2002, s. 4643–4648, DOI: 10.1200/JCO.2002.11.013, PMID: 12488408 [dostęp 2024-04-30] (ang.).
SeiichiS. Yoshida SeiichiS., KenK. Morii KenK., Intrathecal chemotherapy for patients with meningeal carcinomatosis, „Surgical Neurology”, 63 (1), 2005, s. 52–55, DOI: 10.1016/j.surneu.2004.06.011, PMID: 15639526 [dostęp 2024-04-30] (ang.).
Jin HyunJ.H. Park Jin HyunJ.H. i inni, Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era, „Lung Cancer”, 76 (3), 2012, s. 387–392, DOI: 10.1016/j.lungcan.2011.11.022, PMID: 22186628 [dostęp 2024-04-30] (ang.).
EmelineE. Pape EmelineE. i inni, Leptomeningeal metastasis in melanoma: a prospective clinical study of nine patients, „In Vivo”, 26 (6), 2012, s. 1079–1086, PMID: 23160697 [dostęp 2024-04-30] (ang.).
Brian J.B.J. Scott Brian J.B.J., SantoshS. Kesari SantoshS., Leptomeningeal metastases in breast cancer, „American Journal of Cancer Research”, 3 (2), 2013, s. 117–126, PMID: 23593536, PMCID: PMC3623833 [dostęp 2024-04-30] (ang.).
KatelynK. Chitwood KatelynK., JeremyJ. Etzkorn JeremyJ., GeorgeG. Cohen GeorgeG., Topical and Intralesional Treatment of Nonmelanoma Skin Cancer: Efficacy and Cost Comparisons, „Dermatologic Surgery”, 39 (9), 2013, s. 1306–1316, DOI: 10.1111/dsu.12300, PMID: 23915332 [dostęp 2024-04-30] (ang.).
J.H.J.H. Goldie J.H.J.H., A.J.A.J. Coldman A.J.A.J., A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate, „Cancer Treatment Reports”, 63 (11-12), 1979, s. 1727–1733, PMID: 526911 [dostęp 2024-04-30] (ang.).
S.W.S.W. Lowe S.W.S.W. i inni, p53-dependent apoptosis modulates the cytotoxicity of anticancer agents, „Cell”, 74 (6), 1993, s. 957–967, DOI: 10.1016/0092-8674(93)90719-7, PMID: 8402885 [dostęp 2024-04-30] (ang.).
C.C. Dumontet C.C., B.I.B.I. Sikic B.I.B.I., Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death, „Journal of Clinical Oncology”, 17 (3), 1999, s. 1061–1070, DOI: 10.1200/JCO.1999.17.3.1061, PMID: 10071301 [dostęp 2024-04-30] (ang.).
M.M.M.M. Keane M.M.M.M. i inni, Chemotherapy augments TRAIL-induced apoptosis in breast cell lines, „Cancer Research”, 59 (3), 1999, s. 734–741, PMID: 9973225 [dostęp 2024-04-30] (ang.).
A.B.A.B. Pardee A.B.A.B., Growth dysregulation in cancer cells, „Advances in Cancer Research”, 65, 1994, s. 213–228, DOI: 10.1016/s0065-230x(08)60070-6, PMID: 7879668 [dostęp 2024-04-30] (ang.).
Y.A.Y.A. Luqmani Y.A.Y.A., Mechanisms of drug resistance in cancer chemotherapy, „Medical Principles and Practice”, 14 Suppl 1, 2005, s. 35–48, DOI: 10.1159/000086183, PMID: 16103712 [dostęp 2024-04-30] (ang.).
SarojS. Vadhan-Raj SarojS., Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents, „Seminars in Hematology”, 46 (1 Suppl 2), 2009, S26–32, DOI: 10.1053/j.seminhematol.2008.12.007, PMID: 19245931 [dostęp 2024-04-30] (ang.).
D.D. Cella D.D., Factors influencing quality of life in cancer patients: anemia and fatigue, „Seminars in Oncology”, 25 (3 Suppl 7), 1998, s. 43–46, PMID: 9671330 [dostęp 2024-04-30] .
HeinzH. Ludwig HeinzH. i inni, The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients, „European Journal of Cancer”, 40 (15), 2004, s. 2293–2306, DOI: 10.1016/j.ejca.2004.06.019, PMID: 15454256 [dostęp 2024-04-30] (ang.).
Patricia K.P.K. Corey-Lisle Patricia K.P.K. i inni, Transfusions and patient burden in chemotherapy-induced anaemia in France, „Therapeutic Advances in Medical Oncology”, 6 (4), 2014, s. 146–153, DOI: 10.1177/1758834014534515, PMID: 25057301, PMCID: PMC4107713 [dostęp 2024-04-30] (ang.).
J.E.J.E. Groopman J.E.J.E., L.M.L.M. Itri L.M.L.M., Chemotherapy-induced anemia in adults: incidence and treatment, „Journal of the National Cancer Institute”, 91 (19), 1999, s. 1616–1634, DOI: 10.1093/jnci/91.19.1616, PMID: 10511589 [dostęp 2024-04-30] (ang.).
David H.D.H. Henry David H.D.H., The role of intravenous iron in cancer-related anemia, „Oncology”, 20 (8 Suppl 6), 2006, s. 21–24, PMID: 16925107 [dostęp 2024-04-30] (ang.).
George M.G.M. Rodgers George M.G.M. i inni, Cancer- and chemotherapy-induced anemia, „Journal of the National Comprehensive Cancer Network”, 6 (6), 2008, s. 536–564, DOI: 10.6004/jnccn.2008.0042, PMID: 18597709 [dostęp 2024-04-30] (ang.).
LianaL. Scialdone LianaL., Overview of supportive care in patients receiving chemotherapy: antiemetics, pain management, anemia, and neutropenia, „Journal of Pharmacy Practice”, 25 (2), 2012, s. 209–221, DOI: 10.1177/0897190011431631, PMID: 22307093 [dostęp 2024-04-30] (ang.).
JohanJ. Vansteenkiste JohanJ. i inni, Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy, „Journal of the National Cancer Institute”, 94 (16), 2002, s. 1211–1220, DOI: 10.1093/jnci/94.16.1211, PMID: 12189224 [dostęp 2024-04-30] (ang.).
MichaelM. Hedenus MichaelM. i inni, Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study, „British Journal of Haematology”, 122 (3), 2003, s. 394–403, DOI: 10.1046/j.1365-2141.2003.04448.x, PMID: 12877666 [dostęp 2024-04-30] (ang.).
L.L. Gomez L.L., R.R. Martino R.R., K.V.K.V. Rolston K.V.K.V., Neutropenic enterocolitis: spectrum of the disease and comparison of definite and possible cases, „Clinical Infectious Diseases”, 27 (4), 1998, s. 695–699, DOI: 10.1086/514946, PMID: 9798018 [dostęp 2024-04-30] (ang.).
H. Jervoise N.H.J.N. Andreyev H. Jervoise N.H.J.N. i inni, Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer, „Gut”, 61 (2), 2012, s. 179–192, DOI: 10.1136/gutjnl-2011-300563, PMID: 22057051, PMCID: PMC3245898 [dostęp 2024-04-30] (ang.).
ZhiyongZ. Li ZhiyongZ. i inni, Colitis in patients with breast carcinoma treated with taxane-based chemotherapy, „Cancer”, 101 (7), 2004, s. 1508–1513, DOI: 10.1002/cncr.20546, PMID: 15378497 [dostęp 2024-04-30] (ang.).
HarmeetH. Kaur HarmeetH. i inni, Radiologic findings in taxane induced colitis, „European Journal of Radiology”, 66 (1), 2008, s. 75–78, DOI: 10.1016/j.ejrad.2007.04.024, PMID: 17553645 [dostęp 2024-04-30] (ang.).
ElisabethE. Schellhaas ElisabethE. i inni, Bowel perforation in non-small cell lung cancer after bevacizumab therapy, „Investigational New Drugs”, 27 (2), 2009, s. 184–187, DOI: 10.1007/s10637-008-9162-z, PMID: 18665327 [dostęp 2024-04-30] (ang.).
Kimberly E.K.E. Beck Kimberly E.K.E. i inni, Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4, „Journal of Clinical Oncology”, 24 (15), 2006, s. 2283–2289, DOI: 10.1200/JCO.2005.04.5716, PMID: 16710025, PMCID: PMC2140223 [dostęp 2024-04-30] (ang.).
Julian H.J.H. Slade Julian H.J.H. i inni, Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury, „Clinical Colorectal Cancer”, 8 (4), 2009, s. 225–230, DOI: 10.3816/CCC.2009.n.038, PMID: 19822514 [dostęp 2024-04-30] (ang.).
A.Y.A.Y. Lee A.Y.A.Y., M.N.M.N. Levine M.N.M.N., The thrombophilic state induced by therapeutic agents in the cancer patient, „Seminars in Thrombosis and Hemostasis”, 25 (2), 1999, s. 137–145, DOI: 10.1055/s-2007-994915, PMID: 10357081 [dostęp 2024-04-30] (ang.).
Doranne L.D.L. Hilarius Doranne L.D.L. i inni, Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study, „Supportive Care in Cancer”, 20 (1), 2012, s. 107–117, DOI: 10.1007/s00520-010-1073-9, PMID: 21258948, PMCID: PMC3223596 [dostęp 2024-04-30] (ang.).
LorenzoL. Cohen LorenzoL. i inni, Chemotherapy-induced nausea and vomiting—incidence and impact on patient quality of life at community oncology settings, „Supportive Care in Cancer”, 15 (5), 2007, s. 497–503, DOI: 10.1007/s00520-006-0173-z, PMID: 17103197 [dostęp 2024-05-02] (ang.).
CaroleC. Farrell CaroleC. i inni, The impact of chemotherapy-related nausea on patients' nutritional status, psychological distress and quality of life, „Supportive Care in Cancer”, 21 (1), 2013, s. 59–66, DOI: 10.1007/s00520-012-1493-9, PMID: 22610269 [dostęp 2024-05-02] (ang.).
BrigitteB. Bloechl-Daum BrigitteB. i inni, Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment, „Journal of Clinical Oncology”, 24 (27), 2006, s. 4472–4478, DOI: 10.1200/JCO.2006.05.6382, PMID: 16983116 [dostęp 2024-05-02] (ang.).
S.M.S.M. Fox S.M.S.M. i inni, Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy, „Journal of Clinical Oncology”, 11 (12), 1993, s. 2391–2395, DOI: 10.1200/JCO.1993.11.12.2391, PMID: 8246028 [dostęp 2024-05-02] (ang.).
KarinK. Jordan KarinK., ChristophCh. Sippel ChristophCh., Hans-JoachimH.J. Schmoll Hans-JoachimH.J., Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations, „The Oncologist”, 12 (9), 2007, s. 1143–1150, DOI: 10.1634/theoncologist.12-9-1143, PMID: 17914084 [dostęp 2024-05-02] (ang.).
EthanE. Basch EthanE. i inni, Antiemetics: american society of clinical oncology clinical practice guideline update, „Journal of Oncology Practice”, 7 (6), 2011, s. 395–398, DOI: 10.1200/JOP.2011.000397, PMID: 22379425, PMCID: PMC3219469 [dostęp 2024-05-02] (ang.).
F.F. Roila F.F. i inni, Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference, „Annals of Oncology”, 17 (1), 2006, s. 20–28, DOI: 10.1093/annonc/mdj078, PMID: 16314401 [dostęp 2024-05-02] (ang.).
MariaM. Florescu MariaM., MirceaM. Cinteza MirceaM., DragosD. Vinereanu DragosD., Chemotherapy-induced Cardiotoxicity, „Maedica”, 8 (1), 2013, s. 59–67, PMID: 24023601, PMCID: PMC3749765 [dostęp 2024-05-02] (ang.).
SergioS. Cozzi SergioS. i inni, Management of neoplastic pericardial effusions, „Tumori”, 96 (6), 2010, s. 926-929, PMID: 21388053 [dostęp 2024-05-05] (ang.).
Marwan M.M.M. Refaat Marwan M.M.M., William E.W.E. Katz William E.W.E., Neoplastic pericardial effusion, „Clinical Cardiology”, 34 (10), 2011, s. 593–598, DOI: 10.1002/clc.20936, PMID: 21928406, PMCID: PMC6652358 [dostęp 2024-05-05] (ang.).
Hamilton S.H.S. Gillespie Hamilton S.H.S., Christopher J.Ch.J. McGann Christopher J.Ch.J., Brent D.B.D. Wilson Brent D.B.D., Noninvasive diagnosis of chemotherapy related cardiotoxicity, „Current Cardiology Reviews”, 7 (4), 2011, s. 234–244, DOI: 10.2174/157340311799960672, PMID: 22758624, PMCID: PMC3322441 [dostęp 2024-05-05] (ang.).
AdrianaA. Albini AdrianaA. i inni, Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention, „Journal of the National Cancer Institute”, 102 (1), 2010, s. 14–25, DOI: 10.1093/jnci/djp440, PMID: 20007921, PMCID: PMC2802286 [dostęp 2024-05-05] (ang.).
V.B.V.B. Pai V.B.V.B., M.C.M.C. Nahata M.C.M.C., Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention, „Drug Safety”, 22 (4), 2000, s. 263–302, DOI: 10.2165/00002018-200022040-00002, PMID: 10789823 [dostęp 2024-05-05] (ang.).
AxelA. Schlitt AxelA. i inni, Cardiotoxicity and oncological treatments, „Deutsches Arzteblatt International”, 111 (10), 2014, s. 161–168, DOI: 10.3238/arztebl.2014.0161, PMID: 24666651, PMCID: PMC3971565 [dostęp 2024-05-05] (ang.).
R.R. Jeyaseelan R.R. i inni, Molecular mechanisms of doxorubicin-induced cardiomyopathy. Selective suppression of Reiske iron-sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes, „Journal of Biological Chemistry”, 272 (9), 1997, s. 5828–5832, DOI: 10.1074/jbc.272.9.5828, PMID: 9038198 [dostęp 2024-05-05] (ang.).
J.H.J.H. Doroshow J.H.J.H., G.Y.G.Y. Locker G.Y.G.Y., C.E.C.E. Myers C.E.C.E., Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin, „The Journal of Clinical Investigation”, 65 (1), 1980, s. 128–135, DOI: 10.1172/JCI109642, PMID: 7350193, PMCID: PMC371347 [dostęp 2024-05-05] (ang.).
DirkD. Lebrecht DirkD. i inni, Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy, „Circulation”, 108 (19), 2003, s. 2423–2429, DOI: 10.1161/01.CIR.0000093196.59829.DF, PMID: 14568902 [dostęp 2024-05-05] (ang.).
Karlijn A.K.A. Wouters Karlijn A.K.A. i inni, Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies, „British Journal of Haematology”, 131 (5), 2005, s. 561–578, DOI: 10.1111/j.1365-2141.2005.05759.x, PMID: 16351632 [dostęp 2024-05-05] (ang.).
Aarif Y.A.Y. Khakoo Aarif Y.A.Y. i inni, Cardiotoxicity due to cancer therapy, „Texas Heart Institute Journal”, 38 (3), 2011, s. 253–256, PMID: 21720463, PMCID: PMC3113124 [dostęp 2024-05-05] (ang.).
N.N. Harbeck N.N. i inni, Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy, „Annals of Oncology”, 22 (6), 2011, s. 1250–1258, DOI: 10.1093/annonc/mdq543, PMID: 21112929 [dostęp 2024-05-05] (ang.).
Sandra M.S.M. Swain Sandra M.S.M., Fredrick S.F.S. Whaley Fredrick S.F.S., Michael S.M.S. Ewer Michael S.M.S., Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials, „Cancer”, 97 (11), 2003, s. 2869–2879, DOI: 10.1002/cncr.11407, PMID: 12767102 [dostęp 2024-05-05] (ang.).
Michael R.M.R. Bristow Michael R.M.R. i inni, Early anthracycline cardiotoxicity, „The American Journal of Medicine”, 65 (5), 1978, s. 823–832, DOI: 10.1016/0002-9343(78)90802-1, PMID: 707541 [dostęp 2024-05-05] (ang.).
Seppo W.S.W. Langer Seppo W.S.W., Dexrazoxane for the treatment of chemotherapy-related side effects, „Cancer Management and Research”, 6, 2014, s. 357–363, DOI: 10.2147/CMAR.S47238, PMID: 25246808, PMCID: PMC4168851 [dostęp 2024-05-05] (ang.).
D.D. VonD.D.V. Hoff D.D. VonD.D.V. i inni, Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases, „The American Journal of Medicine”, 62 (2), 1977, s. 200–208, DOI: 10.1016/0002-9343(77)90315-1, PMID: 835599 [dostęp 2024-05-05] (ang.).
MariaM. Volkova MariaM., RaymondR. Russell RaymondR., Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment, „Current Cardiology Reviews”, 7 (4), 2011, s. 214–220, DOI: 10.2174/157340311799960645, PMID: 22758622, PMCID: PMC3322439 [dostęp 2024-05-05] (ang.).
L.C.L.C. Kremer L.C.L.C. i inni, Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study, „Journal of Clinical Oncology”, 19 (1), 2001, s. 191–196, DOI: 10.1200/JCO.2001.19.1.191, PMID: 11134212 [dostęp 2024-05-05] (ang.).
S.E.S.E. Lipshultz S.E.S.E. i inni, Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood, „The New England Journal of Medicine”, 324 (12), 1991, s. 808–815, DOI: 10.1056/NEJM199103213241205, PMID: 1997853 [dostęp 2024-05-05] (ang.).
Paulo J.P.J. Oliveira Paulo J.P.J. i inni, Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity, „Toxicology and Applied Pharmacology”, 200 (2), 2004, s. 159–168, DOI: 10.1016/j.taap.2004.04.005, PMID: 15476868 [dostęp 2024-05-05] (ang.).
PaoloP. Spallarossa PaoloP. i inni, Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro, „Journal of Molecular and Cellular Cardiology”, 37 (4), 2004, s. 837–846, DOI: 10.1016/j.yjmcc.2004.05.024, PMID: 15380674 [dostęp 2024-05-05] (ang.).
DanielaD. Cardinale DanielaD. i inni, Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition, „Circulation”, 114 (23), 2006, s. 2474–2481, DOI: 10.1161/CIRCULATIONAHA.106.635144, PMID: 17101852 [dostęp 2024-05-05] (ang.).
M.E.R.M.E.R. O'Brien M.E.R.M.E.R. i inni, Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer, „Annals of Oncology”, 15 (3), 2004, s. 440–449, DOI: 10.1093/annonc/mdh097, PMID: 14998846 [dostęp 2024-05-05] (ang.).
T.T. Safra T.T. i inni, Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2, „Annals of Oncology”, 11 (8), 2000, s. 1029–1033, DOI: 10.1023/a:1008365716693, PMID: 11038041 [dostęp 2024-05-05] .
AbdulfattahA. Saidi AbdulfattahA., RamiR. Alharethi RamiR., Management of chemotherapy induced cardiomyopathy, „Current Cardiology Reviews”, 7 (4), 2011, s. 245–249, DOI: 10.2174/157340311799960681, PMID: 22758625, PMCID: PMC3322442 [dostęp 2024-05-05] (ang.).
J.J. Shapira J.J. i inni, Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation, „Cancer”, 65 (4), 1990, s. 870–873, DOI: 10.1002/1097-0142(19900215)65:4<870::aid-cncr2820650407>3.0.co;2-d, PMID: 2297656 [dostęp 2024-05-05] (ang.).
E.S.E.S. Casper E.S.E.S. i inni, A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors, „Cancer”, 68 (6), 1991, s. 1221–1229, DOI: 10.1002/1097-0142(19910915)68:6<1221::aid-cncr2820680607>3.0.co;2-r, PMID: 1873773 [dostęp 2024-05-05] (ang.).
M.M. Zalupski M.M. i inni, Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study, „Journal of the National Cancer Institute”, 83 (13), 1991, s. 926–932, DOI: 10.1093/jnci/83.13.926, PMID: 2067035 [dostęp 2024-05-05] (ang.).
KashifK. Kalam KashifK., Thomas H.T.H. Marwick Thomas H.T.H., Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis, „European Journal of Cancer”, 49 (13), 2013, s. 2900–2909, DOI: 10.1016/j.ejca.2013.04.030, PMID: 23706982 [dostęp 2024-05-05] (ang.).
S.M.S.M. Swain S.M.S.M. i inni, Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer, „Journal of Clinical Oncology”, 15 (4), 1997, s. 1318–1332, DOI: 10.1200/JCO.1997.15.4.1318, PMID: 9193323 [dostęp 2024-05-05] (ang.).
Barry H.B.H. Trachtenberg Barry H.B.H. i inni, Anthracycline-associated cardiotoxicity in survivors of childhood cancer, „Pediatric Cardiology”, 32 (3), 2011, s. 342–353, DOI: 10.1007/s00246-010-9878-3, PMID: 21221562 [dostęp 2024-05-05] (ang.).
P.D.P.D. King P.D.P.D., M.C.M.C. Perry M.C.M.C., Hepatotoxicity of chemotherapy, „The Oncologist”, 6 (2), 2001, s. 162–176, DOI: 10.1634/theoncologist.6-2-162, PMID: 11306728 [dostęp 2024-05-05] (ang.).
Victor J.V.J. Navarro Victor J.V.J., John R.J.R. Senior John R.J.R., Drug-related hepatotoxicity, „The New England Journal of Medicine”, 354 (7), 2006, s. 731–739, DOI: 10.1056/NEJMra052270, PMID: 16481640 [dostęp 2024-05-05] (ang.).
Sarah E.S.E. James Sarah E.S.E. i inni, Anti-cancer drug induced neurotoxicity and identification of Rho pathway signaling modulators as potential neuroprotectants, „Neurotoxicology”, 29 (4), 2008, s. 605–612, DOI: 10.1016/j.neuro.2008.04.008, PMID: 18539332, PMCID: PMC2615238 [dostęp 2024-05-05] (ang.).
Dawn L.D.L. Hershman Dawn L.D.L. i inni, Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline, „Journal of Clinical Oncology”, 32 (18), 2014, s. 1941–1967, DOI: 10.1200/JCO.2013.54.0914, PMID: 24733808 [dostęp 2024-05-07] (ang.).
MartaM. Seretny MartaM. i inni, Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis, „Pain”, 155 (12), 2014, s. 2461–2470, DOI: 10.1016/j.pain.2014.09.020, PMID: 25261162 [dostęp 2024-05-07] (ang.).
J.S.J.S. Hong J.S.J.S., J.J. Tian J.J., L.H.L.H. Wu L.H.L.H., The influence of chemotherapy-induced neurotoxicity on psychological distress and sleep disturbance in cancer patients, „Current Oncology (Toronto, Ont.)”, 21 (4), 2014, s. 174–180, DOI: 10.3747/co.21.1984, PMID: 25089099, PMCID: PMC4117615 [dostęp 2024-05-07] (ang.).
Janet M.J.M. Schloss Janet M.J.M. i inni, Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): a systematic review, „Clinical Nutrition”, 32 (6), 2013, s. 888–893, DOI: 10.1016/j.clnu.2013.04.007, PMID: 23647723 [dostęp 2024-05-07] (ang.).
A.J.M.A.J.M. Beijers A.J.M.A.J.M., J.L.M.J.L.M. Jongen J.L.M.J.L.M., G.G. Vreugdenhil G.G., Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies, „The Netherlands Journal of Medicine”, 70 (1), 2012, s. 18–25, PMID: 22271810 [dostęp 2024-05-07] (ang.).
LizL. Savage LizL., Chemotherapy-induced pain puzzles scientists, „Journal of the National Cancer Institute”, 99 (14), 2007, s. 1070–1071, DOI: 10.1093/jnci/djm072, PMID: 17623791 [dostęp 2024-05-07] (ang.).
KrzysztofK. Brzeziński KrzysztofK., Polineuropatia wywołana chemioterapią. Część I. Patofizjologia / Chemotherapy-induced polyneuropathy. Part I. Pathophysiology, „Contemporary Oncology”, 16 (1), 2012, s. 72–78, DOI: 10.5114/wo.2012.27341, PMID: 23788859, PMCID: PMC3687382 [dostęp 2024-05-07] (pol. • ang.).
Anthony J.A.J. Windebank Anthony J.A.J., WolfgangW. Grisold WolfgangW., Chemotherapy-induced neuropathy, „Journal of the Peripheral Nervous System”, 13 (1), 2008, s. 27–46, DOI: 10.1111/j.1529-8027.2008.00156.x, PMID: 18346229 [dostęp 2024-05-07] (ang.).
J.E.J.E. Mollman J.E.J.E. i inni, Unusual presentation of cis-platinum neuropathy, „Neurology”, 38 (3), 1988, s. 488–490, DOI: 10.1212/wnl.38.3.488, PMID: 3347355 [dostęp 2024-05-07] (ang.).
S.M.S.M. Grunberg S.M.S.M. i inni, Progressive paresthesias after cessation of therapy with very high-dose cisplatin, „Cancer Chemotherapy and Pharmacology”, 25 (1), 1989, s. 62–64, DOI: 10.1007/BF00694340, PMID: 2556219 [dostęp 2024-05-07] (ang.).
James WJ.W. Albers James WJ.W. i inni, Interventions for preventing neuropathy caused by cisplatin and related compounds, „Cochrane Database of Systematic Reviews”, 2014 (3), 2014, DOI: 10.1002/14651858.CD005228.pub4, PMID: 24687190, PMCID: PMC10891440 [dostęp 2024-05-07] (ang.).
J.P.J.P. Durand J.P.J.P. i inni, Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial, „Annals of Oncology”, 23 (1), 2012, s. 200–205, DOI: 10.1093/annonc/mdr045, PMID: 21427067 [dostęp 2024-05-07] (ang.).
Ellen M. LavoieE.M.L. Smith Ellen M. LavoieE.M.L. i inni, Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial, „Journal of the American Medical Association”, 309 (13), 2013, s. 1359–1367, DOI: 10.1001/jama.2013.2813, PMID: 23549581, PMCID: PMC3912515 [dostęp 2024-05-07] (ang.).
Julie E.J.E. Hammack Julie E.J.E. i inni, Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy, „Pain”, 98 (1-2), 2002, s. 195–203, DOI: 10.1016/s0304-3959(02)00047-7, PMID: 12098632 [dostęp 2024-05-07] (ang.).
Anna-LiisaA.L. Kautio Anna-LiisaA.L. i inni, Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms, „Journal of Pain and Symptom Management”, 35 (1), 2008, s. 31–39, DOI: 10.1016/j.jpainsymman.2007.02.043, PMID: 17980550 [dostęp 2024-05-07] (ang.).
Ravi D.R.D. Rao Ravi D.R.D. i inni, Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3), „Cancer”, 110 (9), 2007, s. 2110–2118, DOI: 10.1002/cncr.23008, PMID: 17853395 [dostęp 2024-05-07] (ang.).
Debra L.D.L. Barton Debra L.D.L. i inni, A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA, „Supportive Care in Cancer”, 19 (6), 2011, s. 833–841, DOI: 10.1007/s00520-010-0911-0, PMID: 20496177, PMCID: PMC3338170 [dostęp 2024-05-07] (ang.).
F.F. Ries F.F., J.J. Klastersky J.J., Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity, „American Journal of Kidney Diseases”, 8 (5), 1986, s. 368–379, DOI: 10.1016/s0272-6386(86)80112-3, PMID: 3538860 [dostęp 2024-05-07] (ang.).
Benjamin D.B.D. Humphreys Benjamin D.B.D., Robert J.R.J. Soiffer Robert J.R.J., Colm C.C.C. Magee Colm C.C.C., Renal failure associated with cancer and its treatment: an update, „Journal of the American Society of Nephrology: JASN”, 16 (1), 2005, s. 151–161, DOI: 10.1681/ASN.2004100843, PMID: 15574506 [dostęp 2024-05-07] (ang.).
VaibhavV. Sahni VaibhavV., DevasmitaD. Choudhury DevasmitaD., ZiauddinZ. Ahmed ZiauddinZ., Chemotherapy-associated renal dysfunction, „Nature Reviews. Nephrology”, 5 (8), 2009, s. 450–462, DOI: 10.1038/nrneph.2009.97, PMID: 19564889 [dostęp 2024-05-07] (ang.).
J.J. Richmond J.J. i inni, Renal lesions associated with malignant lymphomas, „The American Journal of Medicine”, 32, 1962, s. 184–207, DOI: 10.1016/0002-9343(62)90289-9, PMID: 14492019 [dostęp 2024-05-17] (ang.).
TakashiT. Taguchi TakashiT. i inni, Cisplatin-associated nephrotoxicity and pathological events, „Contributions to Nephrology”, 148, 2005, s. 107–121, DOI: 10.1159/000086055, PMID: 15912030 [dostęp 2024-05-17] (ang.).
M.M. Lam M.M., D.J.D.J. Adelstein D.J.D.J., Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin, „American Journal of Kidney Diseases”, 8 (3), 1986, s. 164–169, DOI: 10.1016/s0272-6386(86)80020-8, PMID: 3752072 [dostęp 2024-05-17] (ang.).
H.H. Lajer H.H. i inni, Magnesium depletion enhances cisplatin-induced nephrotoxicity, „Cancer Chemotherapy and Pharmacology”, 56 (5), 2005, s. 535–542, DOI: 10.1007/s00280-005-1010-7, PMID: 15947931 [dostęp 2024-05-17] (ang.).
IstvanI. Arany IstvanI., Robert L.R.L. Safirstein Robert L.R.L., Cisplatin nephrotoxicity, „Seminars in Nephrology”, 23 (5), 2003, s. 460–464, DOI: 10.1016/s0270-9295(03)00089-5, PMID: 13680535 [dostęp 2024-05-17] (ang.).
VincentV. Launay-Vacher VincentV. i inni, Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care, „Cancer Chemotherapy and Pharmacology”, 61 (6), 2008, s. 903–909, DOI: 10.1007/s00280-008-0711-0, PMID: 18317762 [dostęp 2024-05-17] (ang.).
R.R. Skinner R.R. i inni, Ifosfamide, mesna, and nephrotoxicity in children, „Journal of Clinical Oncology”, 11 (1), 1993, s. 173–190, DOI: 10.1200/JCO.1993.11.1.173, PMID: 8418231 [dostęp 2024-05-17] (ang.).
C.B.C.B. Pratt C.B.C.B. i inni, Ifosfamide, Fanconi's syndrome, and rickets, „Journal of Clinical Oncology”, 9 (8), 1991, s. 1495–1499, DOI: 10.1200/JCO.1991.9.8.1495, PMID: 1649270 [dostęp 2024-05-17] (ang.).
R.R. Skinner R.R., Chronic ifosfamide nephrotoxicity in children, „Medical and Pediatric Oncology”, 41 (3), 2003, s. 190–197, DOI: 10.1002/mpo.10336, PMID: 12868118 [dostęp 2024-05-17] (ang.).
MustafaM. Cetiner MustafaM. i inni, Taurine protects against methotrexate-induced toxicity and inhibits leukocyte death, „Toxicology and Applied Pharmacology”, 209 (1), 2005, s. 39–50, DOI: 10.1016/j.taap.2005.03.009, PMID: 15890378 [dostęp 2024-05-17] (ang.).
Benjamin D.B.D. Humphreys Benjamin D.B.D. i inni, Gemcitabine-associated thrombotic microangiopathy, „Cancer”, 100 (12), 2004, s. 2664–2670, DOI: 10.1002/cncr.20290, PMID: 15197810 [dostęp 2024-05-17] (ang.).
Jay H.J.H. Ryu Jay H.J.H., Chemotherapy-induced pulmonary toxicity in lung cancer patients, „Journal of Thoracic Oncology”, 5 (9), 2010, s. 1313–1314, DOI: 10.1097/JTO.0b013e3181e9dbb9, PMID: 20736803 [dostęp 2024-05-17] (ang.).
NavtejN. Sathi NavtejN. i inni, How common is methotrexate pneumonitis? A large prospective study investigates, „Clinical Rheumatology”, 31 (1), 2012, s. 79–83, DOI: 10.1007/s10067-011-1758-6, PMID: 21638023 [dostęp 2024-05-17] (ang.).
MartinM. Schwaiblmair MartinM. i inni, Drug induced interstitial lung disease, „The Open Respiratory Medicine Journal”, 6, 2012, s. 63–74, DOI: 10.2174/1874306401206010063, PMID: 22896776, PMCID: PMC3415629 [dostęp 2024-05-17] (ang.).
BobbakB. Vahid BobbakB., Paul E.P.E. Marik Paul E.P.E., Pulmonary complications of novel antineoplastic agents for solid tumors, „Chest”, 133 (2), 2008, s. 528–538, DOI: 10.1378/chest.07-0851, PMID: 18252919 [dostęp 2024-05-17] (ang.).
Joseph R.J.R. Carver Joseph R.J.R. i inni, American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects, „Journal of Clinical Oncology”, 25 (25), 2007, s. 3991–4008, DOI: 10.1200/JCO.2007.10.9777, PMID: 17577017 [dostęp 2024-05-17] (ang.).
Andrew H.A.H. Limper Andrew H.A.H., Chemotherapy-induced lung disease, „Clinics in Chest Medicine”, 25 (1), 2004, s. 53–64, DOI: 10.1016/S0272-5231(03)00123-0, PMID: 15062597 [dostęp 2024-05-17] (ang.).
S.H.S.H. Abid S.H.S.H., V.V. Malhotra V.V., M.C.M.C. Perry M.C.M.C., Radiation-induced and chemotherapy-induced pulmonary injury, „Current Opinion in Oncology”, 13 (4), 2001, s. 242–248, DOI: 10.1097/00001622-200107000-00006, PMID: 11429481 [dostęp 2024-05-17] (ang.).
Alice DeA.D. Sanctis Alice DeA.D. i inni, Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer, „Cancer”, 117 (14), 2011, s. 3069–3080, DOI: 10.1002/cncr.25894, PMID: 21283982 [dostęp 2024-05-17] (ang.).
J.A. PérezJ.A.P. Fidalgo J.A. PérezJ.A.P. i inni, Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines, „Annals of Oncology”, 23 Suppl 7, 2012, vii167–173, DOI: 10.1093/annonc/mds294, PMID: 22997449 [dostęp 2024-05-17] (ang.).
D.L.D.L. Schrijvers D.L.D.L., Extravasation: a dreaded complication of chemotherapy, „Annals of Oncology”, 14 Suppl 3, 2003, iii26–30, DOI: 10.1093/annonc/mdg744, PMID: 12821535 [dostęp 2024-05-17] (ang.).
LisaL. Schulmeister LisaL., Managing vesicant extravasations, „The Oncologist”, 13 (3), 2008, s. 284–288, DOI: 10.1634/theoncologist.2007-0191, PMID: 18378538 [dostęp 2024-05-17] (ang.).
G.G. Bertelli G.G. i inni, Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study, „Journal of Clinical Oncology”, 13 (11), 1995, s. 2851–2855, DOI: 10.1200/JCO.1995.13.11.2851, PMID: 7595748 [dostęp 2024-05-17] (ang.).
J.J.J.J. Disa J.J.J.J. i inni, Prevention of adriamycin-induced full-thickness skin loss using hyaluronidase infiltration, „Plastic and Reconstructive Surgery”, 101 (2), 1998, s. 370–374, DOI: 10.1097/00006534-199802000-00016, PMID: 9462769 [dostęp 2024-05-17] (ang.).
H.T.H.T. Mouridsen H.T.H.T. i inni, Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies, „Annals of Oncology”, 18 (3), 2007, s. 546–550, DOI: 10.1093/annonc/mdl413, PMID: 17185744 [dostęp 2024-05-17] (ang.).
Ann M.A.M. Berger Ann M.A.M. i inni, NCCN Clinical Practice Guidelines Cancer-related fatigue, „Journal of the National Comprehensive Cancer Network”, 8 (8), 2010, s. 904–931, DOI: 10.6004/jnccn.2010.0067, PMID: 20870636 [dostęp 2024-05-17] (ang.).
RobertoR. Stasi RobertoR. i inni, Cancer-related fatigue: evolving concepts in evaluation and treatment, „Cancer”, 98 (9), 2003, s. 1786–1801, DOI: 10.1002/cncr.11742, PMID: 14584059 [dostęp 2024-05-17] (ang.).
MaartenM. Hofman MaartenM. i inni, Cancer-related fatigue: the scale of the problem, „The Oncologist”, 12 Suppl 1, 2007, s. 4–10, DOI: 10.1634/theoncologist.12-S1-4, PMID: 17573451 [dostęp 2024-05-17] (ang.).
Marianne J.M.J. Hjermstad Marianne J.M.J. i inni, Fatigue in long-term Hodgkin's Disease survivors: a follow-up study, „Journal of Clinical Oncology”, 23 (27), 2005, s. 6587–6595, DOI: 10.1200/JCO.2005.09.936, PMID: 16170166 [dostęp 2024-05-19] (ang.).
Marianne J.M.J. Hjermstad Marianne J.M.J. i inni, Fatigue in long-term Hodgkin's Disease survivors: a follow-up study, „Journal of Clinical Oncology”, 23 (27), 2005, s. 6587–6595, DOI: 10.1200/JCO.2005.09.936, PMID: 16170166 [dostęp 2024-05-17] (ang.).
JulieJ. Lemieux JulieJ., ElizabethE. Maunsell ElizabethE., LouiseL. Provencher LouiseL., Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review, „Psycho-Oncology”, 17 (4), 2008, s. 317–328, DOI: 10.1002/pon.1245, PMID: 17721909 [dostęp 2024-05-17] (ang.).
G.M.G.M. Kiebert G.M.G.M. i inni, Effect of peri-operative chemotherapy on the quality of life of patients with early breast cancer, „European Journal of Cancer”, 26 (10), 1990, s. 1038–1042, DOI: 10.1016/0277-5379(90)90046-v, PMID: 2148877 [dostęp 2024-05-17] (ang.).
N.N. Kluger N.N. i inni, Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients, „Annals of Oncology”, 23 (11), 2012, s. 2879–2884, DOI: 10.1093/annonc/mds095, PMID: 22571858 [dostęp 2024-05-17] (ang.).
E.G.E.G. Grevelman E.G.E.G., W.P.M.W.P.M. Breed W.P.M.W.P.M., Prevention of chemotherapy-induced hair loss by scalp cooling, „Annals of Oncology”, 16 (3), 2005, s. 352–358, DOI: 10.1093/annonc/mdi088, PMID: 15642703 [dostęp 2024-05-17] (ang.).
Manon M.C.M.M.C. Komen Manon M.C.M.M.C. i inni, Factors influencing the effectiveness of scalp cooling in the prevention of chemotherapy-induced alopecia, „The Oncologist”, 18 (7), 2013, s. 885–891, DOI: 10.1634/theoncologist.2012-0332, PMID: 23650021, PMCID: PMC3720643 [dostęp 2024-05-17] (ang.).
C.C. Macduff C.C. i inni, The effectiveness of scalp cooling in preventing alopecia for patients receiving epirubicin and docetaxel, „European Journal of Cancer Care”, 12 (2), 2003, s. 154–161, DOI: 10.1046/j.1365-2354.2003.00382.x, PMID: 12787013 [dostęp 2024-05-17] (ang.).
I.G.I.G. Ron I.G.I.G. i inni, Scalp cooling in the prevention of alopecia in patients receiving depilating chemotherapy, „Supportive Care in Cancer”, 5 (2), 1997, s. 136–138, DOI: 10.1007/BF01262571, PMID: 9069614 [dostęp 2024-05-17] (ang.).
B.B. Satterwhite B.B., S.S. Zimm S.S., The use of scalp hypothermia in the prevention of doxorubicin-induced hair loss, „Cancer”, 54 (1), 1984, s. 34–37, DOI: 10.1002/1097-0142(19840701)54:1<34::aid-cncr2820540109>3.0.co;2-w, PMID: 6372986 [dostęp 2024-05-17] (ang.).
G.G. Witman G.G., E.E. Cadman E.E., M.M. Chen M.M., Misuse of scalp hypothermia, „Cancer Treatment Reports”, 65 (5-6), 1981, s. 507–508, PMID: 7237471 [dostęp 2024-05-17] (ang.).
P.P. Chirac P.P., R.R. Laing R.R., Updating the WHO essential drugs list, „The Lancet”, 357 (9262), 2001, s. 1134, DOI: 10.1016/S0140-6736(00)04291-4, PMID: 11303617 [dostęp 2024-05-17] (ang.).
MonaM. Ridderheim MonaM., MariaM. Bjurberg MariaM., AnitaA. Gustavsson AnitaA., Scalp hypothermia to prevent chemotherapy-induced alopecia is effective and safe: a pilot study of a new digitized scalp-cooling system used in 74 patients, „Supportive Care in Cancer”, 11 (6), 2003, s. 371–377, DOI: 10.1007/s00520-003-0451-y, PMID: 12768403 [dostęp 2024-05-17] (ang.).
M.M. Lemenager M.M. i inni, Effectiveness of cold cap in the prevention of docetaxel-induced alopecia, „European Journal of Cancer”, 33 (2), 1997, s. 297–300, DOI: 10.1016/s0959-8049(96)00374-7, PMID: 9135504 [dostęp 2024-05-17] (ang.).
M.M. Duvic M.M. i inni, A randomized trial of minoxidil in chemotherapy-induced alopecia, „Journal of the American Academy of Dermatology”, 35 (1), 1996, s. 74–78, DOI: 10.1016/S0190-9622(96)90500-9, PMID: 8682968 [dostęp 2024-05-19] (ang.).
C.O.C.O. Granai C.O.C.O. i inni, The use of minoxidil to attempt to prevent alopecia during chemotherapy for gynecologic malignancies, „European Journal of Gynaecological Oncology”, 12 (2), 1991, s. 129–132, PMID: 2055226 [dostęp 2024-05-19] (ang.).
M.M. Hidalgo M.M. i inni, A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia, „Anti-Cancer Drugs”, 10 (4), 1999, s. 393–395, DOI: 10.1097/00001813-199904000-00007, PMID: 10378674 [dostęp 2024-05-19] (ang.).
TeriT. Vega-Stromberg TeriT., Chemotherapy-induced secondary malignancies, „Journal of Infusion Nursing: The Official Publication of the Infusion Nurses Society”, 26 (6), 2003, s. 353–361, DOI: 10.1097/00129804-200311000-00004, PMID: 14624175 [dostęp 2024-05-19] (ang.).
L.B.L.B. Travis L.B.L.B. i inni, Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma, „Journal of the National Cancer Institute”, 87 (7), 1995, s. 524–530, DOI: 10.1093/jnci/87.7.524, PMID: 7707439 [dostęp 2024-05-19] (ang.).
AlissaA. Martin AlissaA. i inni, Secondary malignant neoplasms after high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma, „Pediatric Blood & Cancer”, 61 (8), 2014, s. 1350–1356, DOI: 10.1002/pbc.25033, PMID: 24634399 [dostęp 2024-05-19] (ang.).
S.S. Viviani S.S. i inni, Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD, „European Journal of Cancer & Clinical Oncology”, 21 (5), 1985, s. 601–605, DOI: 10.1016/0277-5379(85)90088-4, PMID: 2408897 [dostęp 2024-05-19] (ang.).
J.J. Wang J.J., K.A.K.A. Galil K.A.K.A., B.P.B.P. Setchell B.P.B.P., Changes in testicular blood flow and testosterone production during aspermatogenesis after irradiation, „The Journal of Endocrinology”, 98 (1), 1983, s. 35–46, DOI: 10.1677/joe.0.0980035, PMID: 6408218 [dostęp 2024-05-19] (ang.).
D.D. Meirow D.D., D.D. Nugent D.D., The effects of radiotherapy and chemotherapy on female reproduction, „Human Reproduction Update”, 7 (6), 2001, s. 535–543, DOI: 10.1093/humupd/7.6.535, PMID: 11727861 [dostęp 2024-05-19] (ang.).
Jonathan L.J.L. Tilly Jonathan L.J.L., Richard N.R.N. Kolesnick Richard N.R.N., Sphingolipids, apoptosis, cancer treatments and the ovary: investigating a crime against female fertility, „Biochimica Et Biophysica Acta”, 1585 (2-3), 2002, s. 135–138, DOI: 10.1016/s1388-1981(02)00333-5, PMID: 12531546 [dostęp 2024-05-19] (ang.).
R.L.R.L. Schilsky R.L.R.L. i inni, Long-term follow up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease, „The American Journal of Medicine”, 71 (4), 1981, s. 552–556, DOI: 10.1016/0002-9343(81)90205-9, PMID: 7282743 [dostęp 2024-05-19] (ang.).
J.J. Byrne J.J. i inni, Early menopause in long-term survivors of cancer during adolescence, „American Journal of Obstetrics and Gynecology”, 166 (3), 1992, s. 788–793, DOI: 10.1016/0002-9378(92)91335-8, PMID: 1550144 [dostęp 2024-05-19] (ang.).
S.J.S.J. Howell S.J.S.J. i inni, Bone mineral density in women with cytotoxic-induced ovarian failure, „Clinical Endocrinology”, 49 (3), 1998, s. 397–402, DOI: 10.1046/j.1365-2265.1998.00550.x, PMID: 9861333 [dostęp 2024-05-19] (ang.).
R.M.R.M. Chapman R.M.R.M., S.B.S.B. Sutcliffe S.B.S.B., Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's disease, „Blood”, 58 (4), 1981, s. 849–851, DOI: 10.1182/blood.V58.4.849.849, PMID: 7272513 [dostęp 2024-05-19] (ang.).
J.H.J.H. Waxman J.H.J.H. i inni, Failure to preserve fertility in patients with Hodgkin's disease, „Cancer Chemotherapy and Pharmacology”, 19 (2), 1987, s. 159–162, DOI: 10.1007/BF00254570, PMID: 31059063105906 [dostęp 2024-05-19] .
J.J. Blatt J.J. i inni, Pregnancy outcome following cancer chemotherapy, „The American Journal of Medicine”, 69 (6), 1980, s. 828–832, DOI: 10.1016/s0002-9343(80)80007-6, PMID: 7446548 [dostęp 2024-05-19] (ang.).
E.E.E.E. Reynoso E.E.E.E. i inni, Acute leukemia during pregnancy: the Toronto Leukemia Study Group experience with long-term follow-up of children exposed in utero to chemotherapeutic agents, „Journal of Clinical Oncology”, 5 (7), 1987, s. 1098–1106, DOI: 10.1200/JCO.1987.5.7.1098, PMID: 3474357 [dostęp 2024-05-19] (ang.).
JosefJ. Warkany JosefJ., Aminopterin and methotrexate: Folic acid deficiency, „Teratology”, 17 (3), 1978, s. 353–357, DOI: 10.1002/tera.1420170314, PMID: 675555 [dostęp 2024-05-19] (ang.).
R.D.R.D. Kozlowski R.D.R.D. i inni, Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease, „The American Journal of Medicine”, 88 (6), 1990, s. 589–592, DOI: 10.1016/0002-9343(90)90522-f, PMID: 2189302 [dostęp 2024-05-19] (ang.).
E.J.E.J. Lammer E.J.E.J. i inni, Retinoic acid embryopathy, „The New England Journal of Medicine”, 313 (14), 1985, s. 837–841, DOI: 10.1056/NEJM198510033131401, PMID: 3162101 [dostęp 2024-05-19] (ang.).
D.R.D.R. Soprano D.R.D.R., K.J.K.J. Soprano K.J.K.J., Retinoids as teratogens, „Annual Review of Nutrition”, 15, 1995, s. 111–132, DOI: 10.1146/annurev.nu.15.070195.000551, PMID: 8527214 [dostęp 2024-05-19] (ang.).
J.J.J.J. Turchi J.J.J.J., C.C. Villasis C.C., Anthracyclines in the treatment of malignancy in pregnancy, „Cancer”, 61 (3), 1988, s. 435–440, DOI: 10.1002/1097-0142(19880201)61:3<435::aid-cncr2820610305>3.0.co;2-f, PMID: 3276379 [dostęp 2024-05-19] (ang.).
F.P.F.P. Li F.P.F.P. i inni, Offspring of patients treated for cancer in childhood, „Journal of the National Cancer Institute”, 62 (5), 1979, s. 1193–1197, DOI: 10.1093/jnci/62.5.1193, PMID: 286096 [dostęp 2024-05-19] (ang.).
Sophie D.S.D. Fosså Sophie D.S.D. i inni, Parenthood in survivors after adulthood cancer and perinatal health in their offspring: a preliminary report, „Journal of the National Cancer Institute. Monographs” (34), 2005, s. 77–82, DOI: 10.1093/jncimonographs/lgi019, PMID: 15784830 [dostęp 2024-05-19] (ang.).
J.J.J.J. Mulvihill J.J.J.J. i inni, Pregnancy outcome in cancer patients. Experience in a large cooperative group, „Cancer”, 60 (5), 1987, s. 1143–1150, DOI: 10.1002/1097-0142(19870901)60:5<1143::aid-cncr2820600537>3.0.co;2-e, PMID: 3607730 [dostęp 2024-05-19] (ang.).
J.J. Aisner J.J., P.H.P.H. Wiernik P.H.P.H., P.P. Pearl P.P., Pregnancy outcome in patients treated for Hodgkin's disease, „Journal of Clinical Oncology”, 11 (3), 1993, s. 507–512, DOI: 10.1200/JCO.1993.11.3.507, PMID: 8445425 [dostęp 2024-05-19] (ang.).
Jeffrey S.J.S. Wefel Jeffrey S.J.S. i inni, The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial, „Cancer”, 100 (11), 2004, s. 2292–2299, DOI: 10.1002/cncr.20272, PMID: 15160331 [dostęp 2024-05-19] (ang.).
Thomas H.T.H. Connor Thomas H.T.H., Melissa A.M.A. McDiarmid Melissa A.M.A., Preventing occupational exposures to antineoplastic drugs in health care settings, „CA: A Cancer Journal for Clinicians”, 56 (6), 2006, s. 354–365, DOI: 10.3322/canjclin.56.6.354, PMID: 17135692 [dostęp 2024-05-19] (ang.).
GeorgeG. Dranitsaris GeorgeG. i inni, Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta-analysis of the literature, „Journal of Oncology Pharmacy Practice: Official Publication of the International Society of Oncology Pharmacy Practitioners”, 11 (2), 2005, s. 69–78, DOI: 10.1191/1078155205jp155oa, PMID: 16465719 [dostęp 2024-05-19] (ang.).
T.T. Skov T.T. i inni, Leukaemia and reproductive outcome among nurses handling antineoplastic drugs, „British Journal of Industrial Medicine”, 49 (12), 1992, s. 855–861, DOI: 10.1136/oem.49.12.855, PMID: 1472444, PMCID: PMC1061216 [dostęp 2024-05-19] (ang.).
T.T. Skov T.T. i inni, Risks for physicians handling antineoplastic drugs, „The Lancet”, 336 (8728), 1990, s. 1446, DOI: 10.1016/0140-6736(90)93148-i, PMID: 1978899 [dostęp 2024-05-19] (ang.).

njmonline.nl

A.J.M.A.J.M. Beijers A.J.M.A.J.M., J.L.M.J.L.M. Jongen J.L.M.J.L.M., G.G. Vreugdenhil G.G., Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies, „The Netherlands Journal of Medicine”, 70 (1), 2012, s. 18–25, PMID: 22271810 [dostęp 2024-05-07] (ang.).

nowotwory.edu.pl

BeataB. Młot BeataB., PiotrP. Rzepecki PiotrP., Kardiotoksyczność leczenia onkologicznego, „Nowotwory”, 60 (6), 2010 [zarchiwizowane z adresu 2015-01-18] .
Marek Z.M.Z. Wojtukiewicz Marek Z.M.Z. i inni, Zespół przewlekłego zmęczenia u chorych na nowotwory poddawanych chemioterapii, „Nowotwory”, 57 (6), 2007, s. 695–701 [zarchiwizowane z adresu 2016-03-04] .

pthit.pl

AdamA. Nowicki AdamA., LidiaL. Gil LidiaL., MieczysławM. Komarnicki MieczysławM., Neutropeniczne zapalenie jelit, „Acta Haematologica Polonica”, 41 (1), 2010, s. 15–20 .

sagepub.com

journals.sagepub.com

SergioS. Cozzi SergioS. i inni, Management of neoplastic pericardial effusions, „Tumori”, 96 (6), 2010, s. 926-929, PMID: 21388053 [dostęp 2024-05-05] (ang.).

termedia.pl

MagdalenaM. Piątkowska MagdalenaM. i inni, Hepatotoksyczność w przebiegu chemioterapii przeciwnowotworowej, „Współczesna Onkologia”, 12 (1), 2009, s. 16–19 [dostęp 2024-05-05] .
BożennaB. Karczmarek-Borowska BożennaB., MałgorzataM. Matczuk MałgorzataM., Postępowanie przy wynaczynieniu leków stosowanych w leczeniu nowotworów, „Współczesna Onkologia”, 8 (1), 2004, s. 29–32 [dostęp 2024-05-17] .

viamedica.pl

czasopisma.viamedica.pl

WładysławW. Sinkiewicz WładysławW., JoannaJ. Banach JoannaJ., Powikłania sercowo-naczyniowe u chorych na raka piersi – aspekty diagnostyczne], „Onkologia w Praktyce Klinicznej”, 6 (4), 2010, s. 171–180 [dostęp 2024-05-05] .

journals.viamedica.pl

KalinaK. Kawecka-Jaszcz KalinaK., AgnieszkaA. Bednarek AgnieszkaA., KatarzynaK. Styczkiewicz KatarzynaK., Postępowanie u chorych onkologicznych obciążonych wywiadem kardiologicznym, „Onkologia w Praktyce Klinicznej”, 5 numer=3, 2009, s. 83–91 [dostęp 2024-05-05] .

web.archive.org

The history of chemotherapy, Cancer Research UK [dostęp 2015-02-10] [zarchiwizowane z adresu 2014-11-10] .
MarcinM. Koba MarcinM., JerzyJ. Konopa JerzyJ., Aktynomycyna D i mechanizmy jej działania, „Postępy Higieny i Medycyny Doświadczalnej”, 59, 2005, s. 290–298, PMID: 15995596 [zarchiwizowane 2017-06-20] .
Chemoregimen.com, Breast Cancer [zarchiwizowane 2015-02-17] .
How is chemotherapy given?, Cancer.org [dostęp 2014-12-02] [zarchiwizowane 2015-03-11] .
JerzyJ. Jarosz JerzyJ. i inni, Wszczepialne systemy dostępu naczyniowego do podawania chemioterapii („porty dożylne”), [w:] Maciej Krzakowski(inne języki), Krzysztof Warzocha (red.), Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych — 2013 r. Tom 1, Gdańsk: Via Medica, 2013, s. 639–651 [zarchiwizowane z adresu 2016-03-17] .
BeataB. Młot BeataB., PiotrP. Rzepecki PiotrP., Kardiotoksyczność leczenia onkologicznego, „Nowotwory”, 60 (6), 2010 [zarchiwizowane z adresu 2015-01-18] .
National CancerN.C. Institute National CancerN.C., Chemotherapy-Induced Peripheral Neuropathy, 2010-02-23 [dostęp 2014-10-24] [zarchiwizowane z adresu 2014-10-24] .
NCI Symptom Management and Quality of Life Steering Committee Chemotherapy-induced Peripheral Neuropathy Clinical Trials Planning Meeting Executive Summary, Cancer.gov [dostęp 2014-10-27] [zarchiwizowane 2014-10-06] (ang.).
Canadian CancerC.C. Society Canadian CancerC.C., Lung damage and chemotherapy [dostęp 2014-11-01] [zarchiwizowane z adresu 2014-11-01] .
JanJ. Bahyrycz JanJ. i inni, Aktualne zalecenia dotyczące profilaktyki i postępowania w przypadku wynaczynienia cytostatyków, „Przegląd Lekarski”, 69 (12), 2012, s. 1283–1286 [zarchiwizowane 2017-12-01] .
AA. Thakur AA., JsJ. Thakur JsJ., Extravasational toxicity of anticancer chemotherapy and its management, „OA Case Reports”, 2 (3), 2013, art. nr 26 [zarchiwizowane 2015-01-18] (ang.).
Marek Z.M.Z. Wojtukiewicz Marek Z.M.Z. i inni, Zespół przewlekłego zmęczenia u chorych na nowotwory poddawanych chemioterapii, „Nowotwory”, 57 (6), 2007, s. 695–701 [zarchiwizowane z adresu 2016-03-04] .

wikidata.org

JerzyJ. Jarosz JerzyJ. i inni, Wszczepialne systemy dostępu naczyniowego do podawania chemioterapii („porty dożylne”), [w:] Maciej Krzakowski(inne języki), Krzysztof Warzocha (red.), Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych — 2013 r. Tom 1, Gdańsk: Via Medica, 2013, s. 639–651 [zarchiwizowane z adresu 2016-03-17] .

wiley.com

onlinelibrary.wiley.com

Sing YuS.Y. Moorcraft Sing YuS.Y., Daniel L.Y.D.L.Y. Lee Daniel L.Y.D.L.Y., DavidD. Cunningham DavidD., Clinical Problems in Oncology: A Practical Guide to Management, DOI: 10.1002/9781118673768.app1, ISBN 978-1-118-67382-9 .

zalecenia.med.pl

onkologia.zalecenia.med.pl

JerzyJ. Jarosz JerzyJ. i inni, Wszczepialne systemy dostępu naczyniowego do podawania chemioterapii („porty dożylne”), [w:] Maciej Krzakowski(inne języki), Krzysztof Warzocha (red.), Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych — 2013 r. Tom 1, Gdańsk: Via Medica, 2013, s. 639–651 [zarchiwizowane z adresu 2016-03-17] .